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ABSTRACT OF THE DISSERTATION
Towards Gene Therapy of Parkinson’s Disease:
Implantation of RUC-GDNF Secreting Mammalian Cell Lines into Rat Brain
by
Hua Liu
Doctor of Philosophy, Graduate Program in Pharmacology
Loma Linda University, December, 2000
Dr. Aladar A. Szalay, Thesis Chairperson

The purpose of this study is to develop a new approach for monitoring the
function of implanted cells by a Renilla luciferase -glial cell line derived neurotrophic
factor (RUC-GDNF) fusion protein in CSF. The RUC-GDNF protein is expected to
report GDNF secreted from the cell by bioluminescence through luciferase activity.
Current ex vivo gene therapy using GDNF is limited by lack of a monitoring
mechanism to determine the expression of GDNF once transformed cells or vector DNA
are injected into animal models. Since the therapeutic concentration of GDNF secreted
into cerebrospinal fluid (CSF) by implanted cells is too low for detection by the
conventional methods such as ELISA and Western blotting, animals must be sacrificed to
retrieve implanted cells in order to study their viability and functionality. Real-time
monitoring of GDNF production by implanted cells in live animals was not possible.
To overcome the limits, a cell line named RG-1 was constructed by permanent
transfection of glial cells with a plasmid DNA construct that contains a fusion gene
encoding the RUC-GDNF fusion protein. The fusion protein is secreted by the RG-1 cell
line and has both GDNF and RUC activity as determined by corresponding bioassays.
The molecular weight of the fusion protein estimated by Western blotting was 70 to 75
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kD, approximately the size of the sum of wild type GDNF and RUC. Concentrations of
GDNF in the fusion protein as measured by ELISA correlate to light emitted by the same
fusion protein as determined by RUC bioassay in the RG-1 culture medium. These
findings indicate the suitability of RUC as the reporter in vitro. The cells were then
stereotactically implanted to the anterior portion of Caudate nucleus of Sprague-Dawley
rats. Cisternal CSF was collected before and up to 45 days after the cellular implantation.
We have obtained the following results: Bioluminescence in cisternal CSF was
first detected at 6 hours post-cell implantation. The luciferase activity peaked at 24 to 48
hours, and then gradually declined after 10 days. Western blotting and ELISA tests failed
to detect GDNF in CSF, suggesting that ELISA and Western blotting methods are
insufficient in detecting GDNF at very low concentration.
This study demonstrates that the transformed glial cell line RG-1 offers the
intrinsic “self-reporting” system for GDNF expression and transport in the rat brain.
RUC secreted enables us to constantly monitor the function of the implanted cells in real
time that promote the survival of dopaminergic cells in Parkinson’s Disease.

CHAPTER L BACKGROUND
A. Parkinson’s Disease (PD)
Idiopathic Parkinson's disease is a progressive neurological disease with many
associated movement symptoms such as tremor, rigidity, bradykinesia, and akinesia. The
primary neurochemical basis of the disease is linked to progressive loss of central
dopamine (DA) containing neurons mainly in the substantia nigra (Homykiewicz 1973;
Homykiewicz 1973). Prior to the onset of the symptoms there is an 80-95% loss of DA
in the striatum in PD patients (Hsu et al. 1976). Depleting DA by reserpine has been
reported to cause a parkinsonism-like syndrome as a dose dependent side effect and was
later used to reproduce Parkinson’s-like symptoms in animals (Goldstein et al. 1975;
Grundig et al. 1976; Brooks et al. 1996; Gerlach et al. 1996). The discovery of the
therapeutic efficacy of levodopa in the alleviation of the symptoms associated with PD
(Muenter et al. 1973; Homykiewicz 1974; Lloyd et al. 1975) came as the strongest
support for the "DA deficiency" hypothesis.
For three decades, levodopa preparations remain the most effective therapy in
alleviating PD symptoms. However, current levodopa treatment aims at only augmenting
striatal DA synthesis and turnover but does not halt the progressive degeneration of nigral
dopaminergic neurons (Ahlskog 1994). Numerous studies have demonstrated that the
supplemental therapy is frequently associated with long-term complications, such as
motor fluctuations and dyskinesias (Marsden et al. 1976; Reilly et al. 1983; Nutt et al.
1997).
Alternative therapeutic approaches such as transplantation of embryonic
substantia nigra neurons or chromaffin cells from the adrenal medulla have been tested
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to ameliorate experimental parkinsonism in both rats (Bjorklund et al. 1979) and primates
(Bankiewicz et al. 1988). In human subjects, transplantation of homologous fetal
substantia nigra cells improves idiopathic Parkinson's disease (Goetz et al. 1989; Freed
et al. 1992; Freed et al. 1992; lacono et al. 1992). This approach was later replaced
largely by posteroventral pallidotomy, for its longer lasting relief of PD symptoms with
less adverse effect (lacono et al. 1994). In summary, current PD therapies targeted at
symptomatic relief have failed to offer neuroprotection or reversal of neuronal cell death.
Circumscribed by the unknown etiopathology of PD, the most effective
therapeutic approach would be to deliver general protection to the degenerating
dopaminergic neurons. This approach would not only offer symptomatic relief by
reviving the dopaminergic neurons and promoting dopaminergic re-innervation to the
striatum, but would also arrest the progression of the disease by protecting dopaminergic
neurons against neurotoxicity as demonstrated in animal studies. This strategy has
received wide attention during recent years (Jimenez-Jimenez et al. 1997; Fahn et al.
1998; Marsden et al. 1998; Stoof et al. 1999; Alexi et al. 2000; Grunblatt et al. 2000).

B. GDNF and Gene Therapy for PD
Recently, new approaches aimed at providing protection to the DA neurons and
restoring function to the remaining neurons have been intensively studied. These
neuroprotective approaches have targeted oxidative stress, neuromelanin, mitochondrial
dysfunction, calcium-binding protein deficiency, nitric oxide, and so on. The most
effective neuroprotection tested in animals to date came from exogenous GDNF
treatment. This holds great hope in the battle against Parkinson’s Disease.
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1. Source, distribution, and transportation
GDNF is a recently identified member of the transforming growth factor-beta
(TGF-(3) family. It was purified from conditioned culture media of B49, a rat glioma cell
line, on the basis of its promotion of high-affinity DA uptake in cultures of embryonic
day 16 rat ventral mesencephalon (Lin et al. 1993). The wild type GDNF is a
glycosylated homodimer which was shown to have a migration of 35kD on SDS-PAGE
(Lin et al. 1994). The distributions of GDNF mRNA in rodent CNS have been found to
be located in the striatum, hippocampus, cortex, hypothalamus, and spinal cord (Springer
et al. 1994).
Although it remains to be demonstrated that deficiency of GDNF is linked to PD
(Hunot et al. 1996; Moore et al. 1996; Lipton et al. 1999), the trophic effect of substantia
nigra glia on DA cells in vitro (O'Malley et al. 1991) supports the hypothesis that
degenerative disorders such as PD result from decreased availability, access, or
responsiveness to specific survival factors (Garvey et al. 1993). The fact that postnatal
striatum appears to have the highest level of GDNF among tissues studied {substantia
nigra, basal forebrain, cortex) suggests a role for GDNF in both local and target-derived
support of DA neurons (Schaar et al. 1993).
GDNF has also been thought to be transported retrogradely along the axon back
to nigral tyrosine hydroxylase (TH)-positive cell bodies and dendrites in rats (Tomac et
al. 1995), as would be expected of a target-derived trophic factor for DA neurons in vivo.
The trophic effect of GDNF was further supported by studies in monkeys in which
injection of GDNF into ventricles resulted in a rapid selective localization of GDNF to
the substantia nigra, cerebellum, and spinal cord (Lapchak et al. 1997e).
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2. Bioactivities of GDNF
Numerous studies have demonstrated that GDNF may prevent nigrostriatal
degeneration and actually reverse the behavioral abnormalities associated with the
nigrostriatal degeneration by increasing the function of remaining dopaminergic neurons
(reviewed by Bohn, 1999). These studies have indicated that GDNF has great potential
as a useful therapy for Parkinson's disease.
In vitro studies using developing superior cervical and dorsal root ganglion cells
demonstrated various degrees of neurite outgrowth and TH+ neuronal survival following
treatment with recombinant GDNF (Trupp et al. 1995; Kaddis et al. 1996). This
corroborates the evidence that GDNF mRNA is expressed by glial cells at high levels in
post-natal day 1 rat ganglia (Springer et al. 1994). In animal studies, GDNF elicited a
dose-dependent increase in the outgrowth of GDNF-preincubated nigral grafts in oculo
(Price et al. 1996), sprouting of TH+ neurons, and increased DA turnover in the adult rat
nigrostriatal system (Beck et al. 1995; Hudson et al. 1995).
3. Protection against neurotoxins
Based on the dopamine-deficiency theory, PD animal models are generated by
injecting either l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) or 6hydroxydopamine (6-OHDA) into animals to induce a dopaminergic neuron degeneration
with high selectivity. GDNF was found to not only promote re-growth of dopaminergic
fibers damaged by MPP+, an MPTP metabolite, in culture (Hou et al. 1996), but also to
protect the DA system against MPTP in mice (Tomac et al. 1995). Apomorphineinduced rotation, a behavioral symptom commonly used to identify dopaminergic
deficiency, was also reversed by GDNF in rats with lesions in the substantia nigra caused
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by 6-OHDA injection (Hoffer et al. 1994; Hudson et al. 1995). It was reported that even
three months after MPTP administration, GDNF injected into the nigra, caudate, or
ventricle was capable of eliciting significant functional improvements in bradykinesia,
rigidity and postural instability, the cardinal symptoms of PD in both primates and
humans (Gash et al. 1996).
4. Gene therapy using GDNF
With its rescuing effect well established, methods of GDNF delivery into the
brain have been intensively studied. One such method is ex vivo gene therapy in which
cells are modified to express a recombinant protein and are then surgically implanted.
Compared to other major approaches of delivery, namely virus-mediated gene therapy or
direct injection, the ex vivo approach has its obvious advantages, in that it uses well
defined and characterized cell lines and targets a focal brain region {striatum) where
GDNF is expressed at high levels. This local targeting is preferable to whole-brain
infection by a virus. Targeting the striatum by stereotactic surgical implantation of cells
prepared ex vivo is important for simulating GDNF in the brain, because GDNF is a
target-derived factor that maintains dopaminergic innervation to the striatum by its
chemical gradient.
Therapy by the ex vivo approach has the additional advantage of continuous
GDNF delivery which direct injection cannot possibly achieve. Since repeated injection
into the brain is not feasible, ex vivo gene therapy is superior and can replace direct
injection.
A great number of trials of ex vivo GDNF gene therapy in animals have been
conducted (Arenas et al. 1995; Lindner et al. 1995; Lapchak 1996a-c; Perez et al. 1996;

5

Lapchak et al. 1997a-e; Lapchak 1998). The majority of these studies yielded very
similar and encouraging results that have clearly demonstrated a profound
neuroprotective effect of exogenous GDNF on TH+ cells in the brain with either MPTP or
6-OHDA lesions.
5. Challenges to the existing ex vivo approach and the proposed experiments
Despite early success of ex vivo GDNF gene therapy, previous studies provided
no means to monitor the viability and functionality of the implanted cells in vivo other
than post-mortem biopsy. In all of the studies discussed above, the expression of a given
protein in the body fluid, e.g., cerebrospinal fluid, was determined by Western blotting
and/or ELISA, the latter being the most sensitive and specific method to quantify GDNF
produced by implanted cells. The detection limit of ELISA using an available
commercial kit (GDNF Emax hnmunoAssay System, Promega) is 32 pg/ml, while the
concentration of GDNF in culture needed to support survival of DA neurons ranges from
10 to 10000 pg/ml (Bohn 1999). Since there is at least a 103-fold dilution once a protein
diffuses from the tissue matrix into the cerebrospinal fluid, the highest possible
concentration of GDNF in CSF is merely 10 pg/ml, significantly below the detection
limit of ELISA.
Therefore, a sensitive intrinsic reporter system that enables us to study the
kinetics of GDNF expression in mammalian cells after implantation, and to trace
implanted cells (such as replication, migration) in living animals would be highly desired.
Such an intrinsic reporter system could also be used to study factors affecting posttranslational modifications, regulation of the secretion of GDNF, and protein-protein
interaction (such as GDNF-receptor binding).
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C. Renilla Luciferase as the Intrinsic Reporter for GDNF Expression
Any ideal reporter system is expected to have these properties {see Table 1):
1. sensitive
2. selective
3. readily available
4. simple detection and quantification procedure
5. low cost
In this study, Renilla luciferase was chosen because 1) it offers high sensitivity
and low background in mammalian cells and body fluids, particularly cerebrospinal fluid;
2) the substrate is readily available; 3) it can be simply detected and quantified; and 4) it
has a relatively low cost. These properties are far superior to other reporter systems and
its advantages are unmatched by the immunoreaction based methods.
1. Renilla luciferase
This enzyme was isolated from the sea pansy Renilla reniformis which catalyzes
reactions that emit blue-green bioluminescence (Matthews et al. 1977). The monomeric
Renilla luciferase protein (36 kDa) catalyzes the oxidative decarboxylation of
coelenterazine in the presence of dissolved oxygen to yield oxyluciferin, CO2, and blue
light (\mcix = 480 nm) in vitro (Matthews et al. 1977; Matthews et al. 1977; Lorenz et al.
1991; Lorenz et al. 1996; Inouye et al. 1997).
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Table 1. Advantages and disadvantages of selected reporter systems

Mechanism

Strength

Weakness

CAT

l4C labeled
chloramphenicol

widely validated
easy, reliable, stable

time
consuming

hGH

radio-immunological

easy, quick, less
sensitive than luciferase

in vitro only

(3-galactosidase

colorimetric
fluorescence

sensitive

background

SEAT

bioluminescence
colorimetric

very sensitive

background

GFP

fluorescence

subcellular localization

background,
in vitro only

Luciferase
(other)

bio luminescence

fust, very sensitive
no background

expensive
rapid turn-over

RUC

bioluminescence

fast, most sensitive,
no background

expensive,
rapid turn-over
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2. Renilla luciferase cDNA as reporter gene
Renilla luciferase has been used as a marker of gene expression in bacteria and
mammalian cells (Lorenz et al. 1991; 1996). The Renilla luciferase cDNA has been
fused to various promoters to study gene regulation. In one such study it was fused to
various promoters in C. albicans to study the promoter induction (Srikantha et al. 1996).
If the promoter is inducible, RUC expression is also induced, thus acting as a reporter for
the promoter regulation.
RUC was also fused to the green fluorescence protein (GFP) to study energy
transfer between proteins (Wang 1998). In this type of experiment, the light (480 nm)
that was emitted from the fusion protein catalyzed reaction excites GFP fluorescence.
RUC can also be fused to binding proteins such as insulin-like growth factor binding
protein 6 (IGF-BP6) to study protein-protein interactions, in which the light emitted from
the RUC-catalyzed reaction can be used to excite GFP which is fused to the target protein
such as IGF that brings GFP in close proximity to RUC upon binding to BP6 (A. Szalay,
pers. comm.). Recent studies also used the secreted form RUC (Liu et al 1997) fused
with GFP (Liu et al. 1999) so that the secretion of the fusion protein (i.e., RUC-GFP)
from transformed mammalian cells can be reported.
These studies suggest that proteins in the form of a single polypeptide chain of a
fusion protein in these cases retained their bioactivities. For example, one protein
(protein A) could introduce the pharmacological effect while the other protein (protein B)
could report the production and kinetics of the fusion protein.
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3. RUC-GDNF fusion
Like RUC-GFP, the RUC-GDNF fusion protein can also be constructed in a
similar manner. Our hypothesis is that the bioactivities of both RUC and GDNF would
be retained. If this is true, cells transformed by this fusion construct can be implanted
into the brain to deliver dopaminergic neuroprotection in PD. The viability of the
implanted cells can be monitored by the bioluminescence assay using the recipient’s
lumbar CSF.

D. Significance of This Study
Monitoring of the viability and functioning of implanted cells would be
significant in both research and clinical gene therapy.
Since the mechanism of cell death in PD is still unknown, the implanted cells may
be exposed to the pathological environment of PD that causes the cell death of
dopaminergic neurons. The fate of implanted cells in human subjects cannot be
hypothesized based on animal studies, simply because we do not know whether PD
destroys cells other than dopaminergic neurons. Therefore, monitoring the viability of
the implanted cells would be a major contribution to modem gene therapy for PD in
human patients, as well as other target diseases that can be benefited by cellular
implantation. Success of this study would offer a method to clinically monitor the
progress of a gene therapy that has not been available to date.
This study also has significance for animal studies, because monitoring implanted
cells in real time in live animals enables researchers to screen for long-lasting cells and
expression constmcts (promoters, enhancers, etc.) without having to sacrifice animals.
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This would reduce the number of experimental animals. Secondly, the dose-response
relationship between GDNF and relief of Parkinsonian symptoms can be established.
Lastly, the RUC-GDNF fusion protein secreted by transformed cells or produced by in
vitro translation can be used in receptor-ligand binding studies.

E. Hypothesis
•

RUC-GDNF fusion protein retains bioactivities of both RUG and GDNFRUCGDNF fusion protein can be quantified by RUG activity measurement in vitro and
in vivo

F. Objective and Specific Aims
The objective of this study is two-fold: To construct a GDNF-RUC expressing
mammalian cell line, and to implant this cell line into the brains of rats.
The specific aims included:
1. Construction of plasmid DNA containing the GDNF-RUC fusion
2. Establishment of a permanently transfected cell line
3. Verification of both GDNF and RUC activities of the fusion protein in vitro
4. Stereotactic implantation of tranfected cells into the brains of rats
5. Monitoring of GDNF expression by RUC-catalyzed bioluminescence.
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CHAPTER II. MATERIALS AND METHODS
A. Materials
1. Reagents
Dulbecco’s Modified Eagle’s Medium (DMEM), lx Trypsin-EDTA solution
(0.05% Trypsin, 0.53 mM EDTA-4Na in HESS, without Ca, Mg, NaHCOa) were
purchased from Cellgro, Mediatech Inc. (Herndon, VA). Fetal bovine serum (FBS) was
purchased from GibcoBRL, Life Technologies, Inc. (Gaithersburg, MD). Bacto-tryptone,
Bacto-yeast extract, and Bacto-agar were purchased from Difco, Inc. (Livonia, MI).
Bovine serum albumin (BSA), Ampicillin, aprotinin, Phenylmethyl-sulfonyl
fluoride (PMSF), Triton X-100, P-mercaptoethanol (P-ME), sodium dodecyl sulfate
(SDS), 2-methylbutane, and diethyl pyrocarbonate (DEPC) were purchased from Sigma
Chemical Company (St. Louis, MO). Dithiothreitol (DTT) and FuGENE 6 Transfection
Reagent were purchased from Boehringer Mannheim Corp. (Indianapolis, IN).
Acrylamide, bis-acrylamide, ammonium persulfate, phenol, chloroform,
methanol, were purchased from Fisher Scientific (Tustin, CA). N^N^N’tetramethylethylenediamine (TEMED), Coomassie Brilliant Blue, and Bradford Protein
Determination Reagent were purchased from Bio-Rad Laboratories (Richmond, CA).
DNA molecular weight standards were purchased from New England BioLabs, Inc.
(Beverly, MA).
Ethanol was purchased from AAPER Alcohol & Chemical Co. (Shelbyville, KY).
Isopropanol was purchased from EM Science (Gibbstown, NJ).
AnXx-Renilla luciferase monoclonal and polyclonal antibodies were obtained from
Dr. Yubao Wang, Loma Linda University. Anti-human GDNF monoclonal and
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polyclonal antibodies were purchased from Promega (Madison, WI). Coelenterazine H
was a gift from Dr. D. O’Kane of Mayo Clinic.
All other reagents were obtained from Sigma Chemical Company (St. Louis,
MO), VWR (Brisbane, CA), J.T. Baker Chemical Co. (Phillipsburg, NJ), and Fisher
Scientific (Tustin, CA).
2. Enzymes
All enzymes were purchased from Promega (Madison, WI), New England
Biolabs, Inc. (Beverly, MA), Boehringer Mannheim Corp. (Indianapolis, IN), and
Beckman Instruments, Inc. (Palo Alto, CA). Only the specific applications involved in
this study are described here. Some of the enzymes provided with commercial kits are
not included.
a. Restriction Endonucleases: These restriction enzymes (Type II restriction
endonucleases) cleave double-stranded DNA at specific sites known as
recognition sequences that are usually four to eight nucleotides in length and
display twofold symmetry. Some cleave both strands exactly at the axis of
symmetry, generating fragments of DNA that carry blunt ends; others cleave
each strand at similar locations on opposite sides of the axis of symmetry,
creating fragments of DNA that carry protruding single-stranded termini.
DNA restriction fragments with compatible cohesive termini or blunt ends can
be joined by DNA ligases. The availability of restriction enzymes and DNA
ligases has facilitated the development of recombinant DNA technology, the
dominant approach for studying many basic biological processes.
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b. DNA Polymerase: The large fragment of E. coli DNA polymerase I, also
known as Klenow fragment, was used to facilitate cloning of blunt ended
DNA fragments by filling in the recessed 3’ termini created by digestion of
DNA with restriction enzymes. The Deep Vent DNA polymerase, a
thermostable DNA-dependent DNA polymerase, was used to amplify specific
sequences of DNA in vitro by polymerase chain reaction (PCR) assays.
c. T4 DNA Ligase: Bacteriophage T4 DNA ligase was used to join DNA
molecules with compatible cohesive termini or blunt ends, occurring between
5’-phosphate and 3’-hydroxyl termini.
d. Alkaline Phosphatase: Calf intestinal alkaline phosphatase (CIP) was used to
catalyze the removal of 5’-phosphate residues from DNA fragments to prevent
self-ligation.
e. RNase A: Ribonuclease A is an endoribonuclease that specifically attacks
single-stranded RNA 3’ to pyrimidine residues and cleaves the phosphate
linkage to the adjacent nucleotide. It was used to degrade RNA in plasmid
DNA preparations. DNase-free RNase A was made by dissolving pancreatic
RNase A at a concentration of 10 mg/ml in 10 mM Tris-HCl, pH 7.5, 15 mM
NaCl, heating at 100°C for 15 minutes and cooling slowly to room
temperature. The solution was divided into aliquots and stored at -20°C.
f.

Proteinase K: It was used to degrade proteins in the preparation of nucleic
acids.

3. Plasmid and phagemid vectors
All vectors used are listed in Table 2.
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Table 2. List of constructs.

Construct

Application

Signal Peptide

pGDNFSa

source of GDNF

rat GDNF

pCDNA-src-bp6

source of sRUC

human interleukin-2

pGDNF

intermediary construct for the
construction of pLNCX-sruc-gdnf

human interleukin-2

carries coding cDNA of sRUC and
GDNF

human interleukin-2

pLNCX-sruc-gdnf

pLNCX-gdnf-ruc

carries coding cDNA of GDNF and
RUC

pLNCX

backbone of all expression construct
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rat GDNF

a. pGDNF3a (Figure 1): It was provided by Dr. Martha Bohn of Northwestern
University as gift. The backbone of this vector is pCR Script AMP which was
used as the cloning vector for GDNF. The complete cDNA of rat GDNF
including the signal peptide codons, was inserted to the MCS region (Sma I
715 and SmalllS) to create pGDNF3a. The expression of rat GDNF in E.
coli is driven by the T7 promoter. The prokaryotic selection marker is
Ampicillin. The replication region contains the ColEl origin that codes for
high copy number replication. GDNF cDNA fragment can be excised by PCR
assay to remove the signal peptide sequence from pGDNF3a and add extra
restriction sites for future digestion and ligation reactions.
b. pBabe-Puro (size 5.1 kb, no map available): This vector was provided by Dr.
Karoly Fatyol of Szalay lab. It was used to subclone the Puror, or puromycinN-acetyl-transferase {pac) gene. The Puror cDNA fragment can be excised by
digestion with restriction enzymes Hind III and Cla I.
c. pCDNA-sruc-bp6 (Figure 2): It was provided by Dr. Yubao Wang of Szalay
laboratory. The backbone of this construct is pcDNA3.1(+). The expression
of the transgene is driven by the CMV promoter in eukaryotic cells and the T7
promoter in prokaryotic cells. It contains Neor for mammalian selection, and
Ampr for selection in bacteria. The RUG cDNA fragment can be obtained
either by PCR application, or by digestion with restriction enzymes EcoR I
and Hind ///which are located at the 5’ end and 3’ end of RUC cDNA
fragment respectively.
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Figure 1. Constructs used for GDNF subcloning.
The plasmid construct pGDNF3a of the cDNA encoding the rat GDNF was kindly
provided to us by Dr. Martha Bohn, Northwestern University. The plasmid pGDNF3a
has a phagemid vector pCR-Script Amp backbone which carries the complete cDNA of
rat GDNF including the signal peptide encoding region, inserted into the MGS region
{Small\5 and Smal728). The selection marker for prokaryotes is Ampr ((3-lactamase).
The replication region contains ColEl origin that codes for high copy number replication.
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GGGGGGATCC
CCTGGTGTTG
GGCTTCTCGA
CCCTTCGCGC
GTTTGATGAC
GGTCACCAGA
CAAGCTGCAG
CCAGAGGGGC
TCACTGACTT
TATTGTAGCG
AAAAAATCTG
CATGTTGCAG
AGCCTGGTTT
TATCTGACCC

GGGACTCTAA
CTCCACACCG
AGCGCCCGCC
TGACCAGTGA
GTCATGGATT
TAAACAAGCG
CTGCCAGCCC
AAAAATCGGG
GGGTTTGGGC
GTTCCTGTGA
TCTCGAAGTA
GCCGGTCGCC
ACCATATCCT
TGGTCGACGC

G|ATG[AAGTTA
CGTCTGCCTT
GAAGACCACT
CTCCAATATG
TTATTCAAGC
GCGGCACTTC
AGAGAATTCC
GGTGCGTCTT
TACGAAACCA
AGCGGCCGAG
GAAGGCTAAC
TTCGACGACG
AAGAAAGCAT
GC

single underline: GDNF signal peptide
double underline: mature peptide
box: start and stop codon

18

TGGGATGTCG
CCCGCTGCCC
CCCTCGGCCA
CCCGAAGATT
CACCATCAAA
CTCGAAGAGA
AGAGGGAAAG
AACTGCAATA
AGGAGGAACT
ACAATGTACG
AAGTGACAAG
ACCTGTCGTT
TCCGCTAAAC

TGGCTGTCTG
GCCGGTAAGA
CCGCCGCGTG
ATCCTGACCA
AGACTGAAAA
GAGGAACCGG
GTCGCAGAGG
CACTTAAATG
GATCTTTCGA
ACAAAATACT
GTAGGCCAGG
TTTAGACGAC
GGTGTGGATG

Figure 2. Constructs used for RUC subcloning.
The cloning construct pCDNA-sruc-bp6 (gift from Dr. Yubao Wang of our laboratory) is
based on the plasmid vector pcDNA3.1(+). In this plasmid, the gene fusion construct or
DNA fragment carrying the cDNA region which encodes the RUC protein including
human interleukin-2 (IL-2) signal peptide sequence, was inserted into the MCS region
(Hind /// 911 and Not 12676) to create pCDNA-sruc-bp6. The expression of RUC in E.
coli is obtained by ligating the construct to the T7 promoter, and in mammalian cells the
CMV promoter was used. The plasmid carries the prokaryotic selection marker encoding
P-lactamase for selection of transformants in prokaryotes. The plasmid also carries the
replication region which contains ColEl origin for high copy number replication.
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ATGTACAGGA
CACAAACAGT
ATGATCGAGA
AGATGTAAAC
AGAAAAACAT
CTTCTTATTT
TGTATTATAC
TGGTTCTTAT
AACTTCTTAA
GCTTGTTTGG
AATAGTTCAC
GGCCTGATAT
AAAATGGTTT
AATCATGAGA
TCAAAGAGAA
ATCCCGTTAG
TTATAATGCT
AATCGGATCC
TTTCCTAATA
AGATGCACCT
TTCTCAAAAA

TGCAACTCCT
GCACCTACTG
ACAAAGGAAA
AAATGAATGT
GCAGAAAATG
ATGGCGACAT
CAGATCTTAT
AGGTTACTTG
TTTACCAAAG
CATTTCATTA
GCTGAAAGTG
TGAAGAAGAT
TGGAGAATAA
AAGTTAGAAC
AGGTGAAGTT
TAAAAGGTGG
TATCTACGTG
AGGATTCTTT
CTGAATTTGT
GATGAAATGG
TGAACAATAA

GTCTTGCATT
AATTCAGCTT
CGGATGATAA
TCTTGATTCA
CTGTTATTTT
GTTGTGCCAC
TGGTATGGGC
ATGATTACAA
AAGATCATTT
TAGCTATGAG
TAGTAGATGT
ATTGCGTTGA
CTTCTTCGTG
CAGAAGAATT
CGTCGTCCAA
TAAACCTGAC
CAAGTGATGA
TCCAATGCTA
CAAAGTAAAA
GAAAATATAT

GCACTAAGTC
AAAGATGACT
CTGGTCCGCA
TTTATTAATT
TTTACATGGT
ATATTGAGCC
AAATCAGGCA
ATATCTTACT
TTGTCGGCCA
CATCAAGATA
GATTGAATCA
TCAAATCTGA
GAAACCATGT
TGCAGCATAT
CATTATCATG
GTTGTACAAA
TTTACCAAAA
TTGTTGAAGG
GGTCTTCATT
CAAATCGTTC

single underline: interleukin-2 signal peptide
double underline: mature peptide
box: start and stop codon
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TTGCACTTGT
TCGAAAGTTT
GTGGTGGGCC
ATTATGATTC
AACGCGGCCT
AGTAGCGCGG
AATCTGGTAA
GCATGGTTTG
TGATTGGGGT
AGATCAAAGC
TGGGATGAAT
AGAAGGAGAA
TGCCATCAAA
CTTGAACCAT
GCCTCGTGAA
TTGTTAGGAA
ATGTTTATTG
CGCCAAGAAG
TTTCGCAAGA
GTTGAGCGAG

Figure 3. Expression vector pLNCX
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d. pLNCX (Figure 3): This is the backbone of all mammalian expression vectors
in this study. It is constructed based on elements derived from Moloney
murine leukemia virus (MoMuLV) and Moloney murine sarcoma virus
(MoMuS V), and designed for retroviral gene delivery and expression. In this
study, pLNCX based vectors have been used as a retroviral infection vehicle,
but also in lipid mediated transfection of target cells. When used in retrovirus
mediated infection, pLNCX based vectors can be transfected into a packaging
cell line, and can transiently express, or integrate and stably express, a
transcript containing XF+ (the extended viral packaging signal) a selectable
marker, and the gene of interest. The 5' viral LTR in this vector contains
promoter/enhancer sequences that control expression of the neomycin
resistance (Neor) gene for antibiotic selection in eukaryotic cells. Gene of
interest can be cloned into the multiple cloning sites immediately downstream
of the human cytomegalovirus (CMV) immediate early promoter (Pcmv)pLNCX also includes the Col El origin of replication and E. coli Ampr, or
6eta-lactamase gene for propagation and antibiotic selection in bacteria. The
Hind III, Cla /, and Hpa I are conveniently placed in the MCS region.
4. Competent cells
The competent E. coli strain used for DNA transformation is DH5-alpha (DHsa).
It was purchased from GibcoBRL. The genotype of this strain is F(f)80 lacZAM15
A(lacZYA-argF) U169 deoR recAl endAl hsdR17(rK, mK+)phoA supE44X thi-1 gyrA96
relAl. This is a recombination-deficient strain commonly used for plasmid DNA
transformation with the yield of greater than IxlO9 transformants/pg of monomer pUC19
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DNA in a 100 \x\ transformation reaction. Competent cells were stored at -70°C until
used. Plasmid DNA was introduced to DH5a cells using a heat-shock procedure
according to manufacturer’s instruction.
5. Mammalian Cell Lines
a. COS-7 cells: This cell line was used in transient transfection to test the
plasmid DNA constructs. The COS-7 cells are derived from kidney cells of
the African green monkey, immortalized by transformation with SV40. The
COS-7 cells were purchased from American Type Culture Collection (ATCC,
CRL1651) (Manassas, VA).
This cell line gives high transfection efficiency and high levels of promoter
activation.
b. PO-D17 cells: This is a mouse glial cell line and was kindly supplied by Dr.
Frisa (Case Western Reserve University). PO-D17 was prepared from
neonatal mouse cortical astrocytes immortalized by retrovirus-mediated
transfer of the SV40 large T antigen gene (Frisa et al. 1996). It was chosen
for this study because this cell line retains contact inhibition which is a desired
characteristic in ex vivo gene therapy. This is a desired characteristic for
cellular implants since uninhibited cell growth could lead to a tumor.
Furthermore, because in ex vivo gene therapy, cells are often encapsulated into
polymers to protect the cells from the host immune rejection, overgrowth
could cause the capsule to rupture, and lead to host immune reactions and
tumor-like growth as well.
The ability of this cell line to promote neurite outgrowth was also studied and
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was found to be much attenuated compared to mortal immature astrocyte
(Frisa et al. 1994). The diminished neurite prolongation effect is also a
helpful feature for the purpose of this study, in which cells are screened by
their capability to promote neurite outgrowth, but only after being introduced
by transduction of the fusion transgene. If cells naturally have this capability,
it would add to the experimental difficulties to distinguish the source of this
capability, i.e., intrinsic, or transduced.
The rationale that tansformed glial cells are preferred in gene therapy in CNS
diseases is that these cells can readily adapt to the CNS environment, have
been found to be responsive to brain injury (Segovia et al. 1998) and offer
stable production of growth factors to the host brain (Lin et al. 1997).
c. Other cell lines, including:
NIH/3T3 (mouse fibroblast, supplied by Dr. Alan Escher, Loma Linda
University). This cell line has been the most widely used in transfection
studies for its stability in transgene expression and since it is very well
characterized in terms of growth pattern, production of growth factors, etc.
PC-12 (rat pheochromocytoma, supplied by Dr. Marino DeLeon, Loma Linda
University). This cell line has been used to mimic neuronal cells.
TH-133 (transformed mouse tyrosine hydroxylase expressing fibroblast,
supplied by Dr. Frederich Grummt, University of Wuerzburg, Germany), were
also used to test for transfection efficiency and secretion efficiency of the
fusion protein.
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6. Animals
Animals were used in cellular implantation and cerebrospinal fluid examination
for bioluminescence. Animals are male adult Sprague-Dawley rats weighing
approximately 200 g. They were fed a standard rodent diet and given water ad libitum
and were housed individually before and after surgery, in rodent cages in the animal care
facility of Loma Linda University. All animal-related procedures are in compliance with
the regulations published by Loma Linda University Animal Research Committee (OSR#
70027).

The rationale for rats being used in this study is that rats have been commonly
used to produce the animal model for PD and test new PD drugs and new therapeutic
approaches (Kopin 1987; Gerlach et al. 1996; Loscher et al. 1996). Besides, the CSF
volume in the rat is reasonably sufficient for RUC assay.
7. Primers for PCR and DNA sequencing
All primers (see Table 3) were synthesized by Integrated DNA Technologies, Inc.
Coralville, IA. The concentration of all primers is 20 pmol/pl. Primer stock solutions
were stored at -20°C, and working solutions were stored at 4°C.
Primers were used to specify the region on the DNA template for amplification
and were designed using Omiga 2.1 primer generating program.
8. Kits and systems
Major commercial kits and systems used in this study are listed below. Usages
are described or outlined in the method sections. For further details, please see the
manufacturer’s instructions.
a. Opti-4CN Detection Kit, Goat-anti-Rabbit (BioRad)

26

b. QIAfilter Plasmid Midi and Maxi Kits (Qiagen)
c. QIAquick Gel Extraction Kit (Qiagen)
d. GDNFE max tm ImmunoAssay System (Promega)
e. FuGene 6 Lipofection System (Roche)
9. Supplies
NitroBind nitrocellulose transfer membranes (0.45 micron) were purchased from
MSI (Westboro, MA). Filter paper model 224 25 was purchased from Bio-Rad.
Fisherbrand bacterial culture dishes were purchased from Fisher Scientific. Falcon
vacuum gas plasma treated tissue culture dishes were purchased from Becton Dickinson
and Co. Centriplus concentrators (Model 100) were purchased from Amicon, Inc.
(Beverly, MA).
Hamilton Syringe 701 RN 10 pi and 20 pi and Hamilton Needle 26S gauge were
purchased from VWR Scientific.
10. Solutions
The recipes for solutions are listed as follows. More recipes can be found in the
Methods sections.
a. Ethidium Bromide: 10 mg/ml
b. RUC assay buffer: 0.5M NaCl, ImM EDTA, lOOmM KH2PO4, pH 7.4
c. Luria-Bertani (LB) Medium (per Liter): 10 g of NaCl, 10 g of tryptone, 5 g of

yeast extract, pH adjusted to 7.0; autoclaved for 20 minutes at 15 Ib/sq.in.
d. LB Agar (per Liter): 10 g of NaCl, 10 g of tryptone, 5 g of yeast extract, 20 g
of agar, pH adjusted to 7.0; autoclaved, and poured into petri dishes (~25
ml/100-mm plate).
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e. SOC Medium (per Liter): 10 g of tryptone, 5 g of yeast extract, 5 g of NaCl,
10 mM MgSCL, 10 mM MgC^, pH adjusted to 7.0; autoclaved, and filtersterilized glucose added to a final concentration of 20 mM.
f.

TE buffer: 10 mM Tris-HCl pH 8.0, 1 mM EDTA.

g. TEN buffer: 10 mM Tris-HCl, pH 7.5, 0.1 mM EDTA, 25 mM NaCl.
h. TE-saturated phenol:chloroform:isoamyl alcohol (25:24:1): Mix equal parts of
TE buffer and phenol and allow the phases to separate. Then mix 1 part of the
lower, phenol phase with 1 part of chloroform:isoamyl alcohol (24:1).
i.

Chloroform:isoamyl alcohol (24:1): equal parts of chloroform and isoamyl
alcohol.

j.

Phosphate-buffered saline (PBS) (per Liter): 8 g of NaCl, 0.2 g of KC1, 1.44 g
ofNa2HP04, and 0.24 g of KH2PO4, pH adjusted to 7.4.

k. lx PBST: lx Phosphate-buffered saline, 0.1% Tween 20.
1.

Tris-buffered saline (TBS): 20 mM Tris, 500 mM NaCl, pH 7.5.

m. lx TEST: lx Tris-buffered saline, 0.1% Tween 20.
n. 1M phosphoric acid (GDNF ELISA)
o. Block & Sample Buffer (GDNF ELISA): purchased from Promega
p. Extraction buffer (for genomic DNA extraction): 10 mM Tris-HCl pH 8.0,
lOOmM EDTA pH 8.0, 20 pg/ml pancreatic RNAase, 0.5% SDS.
q. 20x SSC (per liter): 175.3 g of NaCl, 88.2 g of sodium citrate, pH adjusted to
7.0.

r. 2x SDS gel-loading buffer: 100 mM Tris-HCl pH 6.8, 200 mM dithiothreitol
(DTT), 4% SDS, 0.2% bromophenol blue, 20% glycerol.
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s. Tris-glycine electrophoresis buffer (pH 8.3): 25 mM Tris base, 250 mM
glycine, 0.1% SDS.
t.

Transfer buffer (pH 8.3) (for Western blotting): 39 mM glycine, 48 mM Tris
base, 0.037% SDS, 20% methanol.

u. Blocking buffer (for Western blotting): 1% BSA in lx PBS.
v. Antibody dilution buffer (for Western blotting): 1% BSA in lx PBST.
w. 0.5x TBE: 0.045 M Tris, 0.045 M boric acid, 1 mM EDTA (pH 8.0).
x. Single-detergent lysis buffer: 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.02%
sodium azide, 100 pg/ml phenylmethylsulfonyl fluoride (PMSF), 1 pg/ml
aprotinin, 1% Triton X-100. PMSF should be added to the lysis buffer just
before use.
y. Solution I (for plasmid miniprep): 25 mM Tris-HCl pH 8.0, 10 mM EDTA, 50
mM glucose.
z. Solution II (for plasmid miniprep): 0.1 N NaOH, 1% SDS.
aa. Solution III (for plasmid miniprep) (per 100 ml): 60 ml of 5 M potassium
acetate, 11.5 ml of glacial acetic acid, 28.5 ml of H2O.
bb. Cracking 2x buffer (per 50 ml): 2 ml of 5 M NaOH, 2.5 ml of 10% SDS, 10 g
of sucrose.
11. Anesthetics
Halothane was supplied by Halo Carbon Laboratories (River Edge, NJ).
Pentabarbital (Nembutal) was purchased from Abbot Laboratories (North Chicago, IL).
Bupivacaine & Epinephrine 0.5% was purchased from Loma Linda University Medical
Center.
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All controlled substances were used and stored in accordance with the regulations
posted by Loma Linda University Animal Research Committee and Loma Linda
University Biosafety Committee.
12. Gels
a. 1% agarose gel (50 ml): 0.5 g of agarose dissolved in 50 ml of 0.5x TBE.
Running buffer: 0.5x TBE.
b. 8% polyacrylamide gel (10 ml): mix 2.66 ml of 30% acrylamide mix, 5.27 ml
of water, 2 ml of 5x TBE, 0.07 ml of 10% ammonium persulfate, and 6 pi of
TEMED. Running buffer: lx TBE.
c.

12% polyacrylamide resolving gel (10 ml): mix 4 ml of 30% acrylamide mix,
3.3 ml of water, 2.5 ml of 1.5 M Tris (pH 8.8), 0.1 ml of 10% SDS, 0.1 ml of
10% ammonium persulfate, and 4 pi of TEMED. Running buffer: Trisglycine electrophoresis buffer.

d. 5% polyacrylamide stacking gel (5 ml): mix 0.83 ml of 30% acrylamide mix,
3.4 ml of water, 0.63 ml of 1 M Tris (pH 6.8), 0.05 ml of 10% SDS, 0.05 ml
of 10% ammonium persulfate, and 5 pi of TEMED. Running buffer: Trisglycine electrophoresis buffer.
13. Equipment
a. Hamamatsu Argus-100 low-light imaging system (Hamamatsu Photonics)
b. Turner TD-20e Luminometer (Turner Designs)
c. FluroMax-3 Spectrofluorometer (ISA Inc.)
14. Computer software and databases
a. Omega 2.1 (Oxford Molecular Ltd.)
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b. Sequencher 3.0 (Gene codes Corporation)
c. BLAST program under www.ncbi.nlm.nih.gov
d. Statistical Product & Service Solutions (SPSS Inc.)

B. Methods
This section details the procedures to 1) engineer the constructs; 2) establish
permanently transfected mammalian cell lines with the constructs; 3) verify both RUC
and GDNF activities in the engineered cells; 4) stereotactically implant the engineered
cells into animal brains and measure the protein production by implanted cells in
cerebrospinal fluid.
1. Engineering of constructs
Two fusion constructs and one drug selection (puromycin) construct were
engineered. The pLNCX-sruc-gdnf was engineered by placing the human CMV
promoter (Pcmv), Renilla luciferase cDNA, and GDNF cDNA fusion cassette into the
plasmid vector pLNCX (Clontech). To facilitate the secretion of RUC-GDNF fusion
protein, the human interleukin-2 signal peptide was fused to the N-terminus of Renilla
luciferase (Liu et al. 1997). The RUC-GDNF-fusion gene contains a 9 bp linker linking
the 3’ end of RUC and the 5’ end of GDNF. To ensure in frame translation and secretion,
the stop codon of RUC and signal peptide codon of GDNF were removed. In addition,
the expression cassette was linked to a poly A fragment. The pLNCX-gdnf-ruc was
engineered much the same way, except in reverse order of GDNF and RUC cDNAs and
the use of GDNF signal peptide for secretion.
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1) Subcloning for GDNF and RUC cDNAs
The constructs, pGDNF3a and pCDNA-sruc-bp6 were used to subclone GDNF
and RUC cDNAs. These constructs were introduced into the DFCa E. coli strain by a
heat shock method to amplify plasmid DNA and thereafter used to obtain GDNF and
RUC cDNAs with certain sequences truncated in order to make the construct to code for
a chimeric secretive protein.
a) Introducing plasmid DNA into E. coli DH5a by heat shock
Fifty nanograms each of plasmid DNA, pGDNF3a and pCDNA-sruc-bp6 was
mixed with 50 pi of DHsa competent cells, and incubated on ice for 30 minutes. The
competent cells were heat shocked by placing the competent cells at 42°C in a water bath
for 1 minute, and then placed on ice for 2 minutes, before adding to 200 pi of SOC
medium and incubating at 37°C with agitation for 1 hour. The cell mixture was plated
onto LB agar plates containing 100 pg/ml ampicillin, and incubated overnight at 37°C.
Single colonies were then incubated overnight in LB bacteria culture medium with
ampicillin at 37°C with vigorous agitation.
b) Isolation of plasmid DNA
About 1.5 ml of the overnight culture was transferred into a microcentrifuge tube
and centrifuged at 12,000xg for 1 minute. The bacterial pellet was resuspended into 100
pi of ice-cold miniprep lysis buffer (solution I), and incubated at room temperature for 5
minutes. Freshly made solution II of 200 pi was then added and mixed by inversion,
followed by incubation on ice for 5 minutes. About 150 pi of ice-cold potassium acetate
solution (solution III), pH 4.8, was added, mixed by inversion, and incubated on ice for 5
minutes. The tube was centrifuged at 12,000xg for 5 minutes and the supernatant was
32

transferred to a fresh tube. DNase-free RNase A was added to a final concentration of 20
jag/ml, and the incubation was carried out at 37°C for 20 minutes. The plasmid DNA was
treated once with 1 volume of TE-saturated phenol:chloroform:isoamyl alcohol (25:24:1),
and once with 1 volume of chloroform:isoamyl alcohol (24:1). The upper, aqueous phase
was then mixed with 2.5 volumes of ethanol. DNA fraction was precipitated and
centrifuged at 12,000xg for 15 minutes. The pellet was rinsed with 70% ethanol and
dried under vacuum. The plasmid DNA was dissolved in sterile deionized water and
stored at -20°C until used.
c) Construction of pLNCX-sruc-gdnf
•

PCR to remove stop codon from RUC

Primer-7 and Primer-8 were designed (Table 3, Figure 4) to amplify RUC cDNA
from pCDNA-sruc-bp6 (Figure 2) with the stop codon removed. The primers were also
designed to add a Hind ///restriction site to the 5’ end and an ATzo / site to the 3’ end of
RUC cDNA. These restriction sites were used to ligate the RUC fragment to the Hind III
site of the vector pLNCX, and to the Xho I site of the 5’ end of GDNF fragment. Please
see Figure 4 for primer-template alignment.
The PCR was set up by mixing the following reagents: 40 pi of sterile deionized
water, 1 pi of plasmid DNA (10 ng/pl), 5 pi of lOx ThermoPol buffer, 1 pi of dNTPs (25
mM each), 1 pi of Primer-7 and 1 pi of Primer-8 (20 pmol/pl), and 1 pi of Deep Vent
DNA Polymerase (2 units/pl). PCR was conducted as programmed in Table 4.
•

PCR to remove signal peptide sequence from cDNA encoding GDNF

Primer-5 and Primer-6 (Table 3, Figure 4) were designed to amplify GDNF
cDNA from pGDNF3a (Figure 1) with the signal peptide sequence removed. The
33

r?

O

o

O
H
o
U
O
^
<

o
o
o

H
<
H
H

to

O

o
O
o

u
<

O

H

<

O

o
u
O
o
u
o

O
o
U
u
o
u

H
H
U

O
H
H

O
<
<

C
<
O

O

g
u
u
o

o
z<
^
^
U

u
f—1
o
u
o

P
o
u
o

u

to
42
C3

H

o
u

b£)
fl
• i-H

C

OT

2
Q
O

Pi

^c
S’

o
bO
C

Pi

o
bij
C

o

bO
_P

(1)

C)

• i-H

• i-H

C

c

o
p

cr
u
ty]

o

p

a"
u
C/3

c

o

42
P
4-h

O

P
03

g

X

Oh

H

u
u
u
H
H
<

UO

O

H

^

O

U

O

U

K

p

jD
M

P2

^

iS
tuo

Vh

C

g
°

bX)

.sa

CJO

42
Pi

^
o
4b

^
o
^

Ph

Vj

M

o

u

• l-H

o

OT

^

Q
O

Q
O

in

43

Vh

'S

p

^
Pi

.sa
P

D
Pi

o
o'
bO

fl
o
p

• r-H

Q

p

cr
(U
Cfl

o&
bO
fl
o

• T-*

c

CD

p

a"
<U
M

bo

4C
P
03

u

^

S-<

i2

• i-H

tL,

O

PB

bo

M

2
Q

<

r,

IT)

o

Ph

to
0

I/O

o

H

Pi

42

H
H

^
P
<
<
O
O

o
VH
£

P

H

H

o
o
H
o
h
O

o
^

<

<

rh

u
o
c
<J
H
P

I/O

o

^
o

^
rh,
H
o
o
O
U

I/O

bO

JU

<

I/O

I

<

to

I/O

c
o

u
o
u
h
u

- H S d Uh °H
°O oo u H U O
U
O p
o ° HH
U
H
^
H
H
<
h
B
I
U
o
H
P <
°
O
^ H
< uu
<
g
H °
C

CO

X

<

I/O

<

<

^

m

42

C4

U
^
<
H

<

P

O

o

t+H

U
U
U
O

h
u
u
u
u

ho

H

»—H

S

to

ro

<!

u

o

42
P

to

u

H
H

C

OJ

o
u
u
u

H
<

H
O
H
H
H

C

o

ro

u
h

P
<

• i-H

Cfl

u
<
u
o

<
U

OJD

P

to

u
u
<
u

H
H

bfi

ro

<
H
H
H
O

OI

sC

03

Uh
03

to

p-

s

tH
03

Ph

Ph

esss
• J—<
•C
• £H

0*

Ph

6
g
C/3
X

u

xhJ

a
34

r-

CO

o-n

03

03

o

Oh
03

D

e

03

e

03

s

s

• r-H

e

• jH

Ph

Ph

Ph

Ph

Ph

Ph

s

Table 4. PCR programs used in this study for cloning and construction and for
sequencing of genomic DNA
Temperature

Length

Cycle
number

1

94 °C

2 min

1

2

94 °C
60 °C
72 °C

30 sec
1 min
2 min

30

3

72 °C

5 min

1

1

94 °C

2 min

1

2

94 °C
55 °C
72 °C

30 sec
1 min
2 min

30

3

72 °C

5 min

1

1

94 °C

2 min

1

2

94 °C
55 °C
72 °C

30 sec
1 min
2 min

30

3

72 °C

5 min
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primers were also designed to add an Xho / restriction site to the 5’ end and a Sal I
restriction site to the 3’ end of GDNF cDNA. These restriction sites were to be used to
ligate the GDNF fragment to the Sal I site of the vector pLNCX, and to the Xho I site of
the 3’ end of RUG fragment. Please see Figure 4 for primer-template alignment.
The PGR products were loaded onto 1% Agarose gel and electrophoresis was
conducted at 80 Volts. The gel was then visualized under UV light for less than 30
seconds and a DNA fragment of 592 bp encoding GDNF, and 1024 bp encoding RUG
respectively, were excised from the gel and purified using QIAquick Gel Extraction Kit.
The purified DNA was then digested with restriction enzymes Xho I and Sal I for GDNF
DNA, and Hind III and Xho I for RUG DNA respectively, to prepare the 5 ’ and 3 ’ ends of
the cDNAs for ligation to the vector DNA.
The restriction reaction was set up generally as follows: 1 pg of PGR product in
lx reaction buffer with 5 to 10 units of corresponding restriction enzymes. The reaction
was carried out at 37°C overnight to ensure complete digestion.
•

Construction of intermediary vector pGDNF

The intermediary vector pGDNF (Figure 6) was engineered to facilitate the
subcloning for pLNCX-sruc-gdnf. The full length GDNF cDNA was excised from
pGDNF3a with restriction enzymes Hind III and Sal /, and blunt-ended by T4 DNA
polymerase according to the manufacturer’s instruction. This cDNA fragment was
ligated to the vector DNA pLNCX, which was predigested with Hpa I (blunt-end
digestion) and dephosphorylated with Alkaline phosphatase to prevent self-ligation.
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Figure 6. RUC-GDNF fusion gene constructs.
All expression constructs are based on pLNCX plasmid DNA.
The vector pLNCX-gdnf (A) was constructed by ligating GDNF cDNA excised from
pGDNF3a to pLNCX, and was used as the intermediary vector to supply the Sal I
restriction site. The vector pLNCX-puro (B) was used to co-transfect mammalian cells
for resistance to puromycin. Expression vectors pLNCX-sruc-gdnf (C, sruc: secretive
RUC) and pLNCX-gdnf-ruc (D) differ in the relative position of RUG and GDNF; and
the signal peptide sequences. In pLNCX-sruc-gdnf the signal peptide sequence is human
interleukin-2 signal peptide encoding sequence, while in pLNCX-gdnf-ruc, the signal
peptide of GDNF.
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•

Digestion of PCR products

The sole purpose of pGDNF in this study is to prepare the vector pLNCX for
subsequent cloning by adding a &//restriction site downstream to the Hind III site in the
MCS region. This vector was then linearized by digestion with Hind III and Sal /,
confirmed by gel electrophoresis, and purified from the gel slice with the QIAquick Gel
Extraction Kit.
•

Ligation of cDNAs to the linearized vector pGDNF

Digested GDNF and RUC cDNAs were ligated to the linearized vector pGDNF in
a ligation reaction which was set up on ice by adding the following reagents in the order
shown: 25 pi of nuclease-free water, a total of 100 ng of vector DNA, GDNF and RUC
cDNAs with molar ratio of 1:3:3, 10 pi of 5x T4 DNA ligase buffer, and 2 pi of T4 DNA
ligase (lunit/pl), nuclease-free water to make final volume of 50 pi. The reagents were
mixed gently, and incubated at 16°C for a minimum of 16 hours.
After incubation, 50 pi of phenol:chloroform:isoamyl alcohol (25:24:1) was
added to the reaction and mixed thoroughly, followed by centrifugation at room
temperature for 5 minutes at 14,000xg. The upper aqueous layer, about 45 pi, was
carefully removed and transferred into a fresh 1.5-ml microcentrifuge tube. In the next
step, 25 pi of 7.5 M NH4OAc and 150 pi of ethanol (-20°C) were added, vortexed
thoroughly, and centrifuged at room temperature for 20 minutes at 14,000xg. The
pelleted DNA was washed with 0.5 ml of 70% ethanol (-20°C), and centrifuged for 2
minutes to remove the supernatant. The cDNA pellet was dried under vacuum, and
dissolved in 10 pi of sterile, distilled water.
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•

Transformation of DH5a cells with pLNCX-sruc-gdnf DNA

An aliquot of 5 \x\ of the ligated cDNA was added to 50 pi (approximately 4x10 )
of competent DH5a cells, and the heat shock procedure was carried out as described
previously to introduce the DNA into the competent cells. The cell mixture was plated
onto LB agar plates supplemented with 100 pg/ml of ampicillin, and incubated overnight
at 37°C. The individual colonies were then subjected to further analysis for confirmation
as presented later.
d) Construction of pLNCX-gdnf-ruc
The construct pLNCX-gdnf-ruc (Figure 6) was engineered by much the same
method used to construct pLNCX-sruc-gdnf. GDNF cDNA was amplified by PCR with
primer-1 and primer-2 (see Table 3, Table 4 and Figure 5) from pGDNF3a (Figure 1).
The GDNF signal peptide sequence was retained but the stop codon removed. A Hind III
and EcoR I site was added to the 5’ and the 3’ ends of GDNF cDNA respectively, to
facilitate the cohesive end ligation of GDNF fragment to RUG fragment and the vector
pLNCX.
The PCR product was then digested with Hind III to prepare the 5 ’ end and
partially digested with EcoR I to prepare the 3 ’ end but also maintain the EcoR I site
within GDNF fragment. The RUC cDNA was prepared by digesting pCDNA-sruc-bp6
(Figure 2) with EcoR I and Hind III. The vector pLNCX was prepared by linearizing
with Hind III and dephosphorylation to prevent self-ligation. The GDNF cDNA and the
RUC cDNA were then ligated to linearized pLNCX. The ligated cDNA pLNCX-gdnfrue was introduced into DH5a cells by the heat shock method and the individual colonies
were picked up for further confirmation.
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e) Construction of pLNCX-puro vector
A drug selection vector pLNCX-puro (Figure 6) that contains Puror coding for
puromycin-N-acetyl-transferase was constructed by inserting Puror into the MCS region
of pLNCX. The full-length Puror DNA was digested from pBabe-Puro with Hind III and
Cla /, and ligated to the corresponding sites on the vector pLNCX which had been
digested with the same enzymes. This construct was made for use as a co-transfection
construct with pLNCX-sruc-gdnf and pLNCX-gdnf-ruc for drug selection purposes.
2) Confirmation of the constructs
The in-frame fusion of RUC-GDNF or GDNF-RUC protein was confirmed by the
corresponding cDNA sequences. The confirmation process was taken through the
following steps.
a) Rapid screening
This procedure allows insertion of cDNA into the vector to be verified. Twenty
individual colonies (10 were shown in Figure 7) from each transformation were randomly
selected for use with the cracking procedure, which allows rapid estimation of plasmid
size (Barnes 1977). The individual colonies were picked with sterile pipette tips,
smeared against the bottom of a microcentrifuge tube, and then streaked onto a fresh
LB/ampicillin plate. The plate was incubated at 37°C for approximately 6 hours to allow
the regeneration of the colonies for later analysis.
A volume of 50 pi of 10 mM EDTA, pH 8.0, was added to each tube containing
individual colonies, and the cells were re-suspended with vortexing. Fifty pi of freshly
made 2x cracking buffer was added to each tube, vortexed, and incubated at 70°C for 5
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Figure 7. Identification of the correct plasmid size after insertion of transgene cDNA by
rapid screening.
Ten individual transformants were tested by rapid screening.
▼ indicates plasmid DNA containing insert.
• indicates plasmid DNA NOT containing insert.
Gel: 1% Agarose.
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minutes. The tubes were cooled down to room temperature, before 1.5pl of 4 M KC1 and
0.5 pi of 0.4% bromophenol blue were added, followed by incubation on ice for 5
minutes, and centrifugation at 12,000xg for 3 minutes at 4°C. About 25-50 pi of each
supernatant was loaded onto a 1 % agarose gel, and the plasmid sizes were estimated
using supercoiled DNA as size markers and non-digested pLNCX as the control.
Clones containing plasmid of larger size were grown in overnight cultures and plasmid
minipreps were done to obtain DNA sufficient for digestion and sequencing.
b) Restriction analysis
Plasmid DNA was digested simultaneously with restriction enzymes Hind III/Xho
I/Sal I for pLNCX-sruc-gdnf and Hind III/EcoR I and BamH I separately for pLNCXgdnf-ruc. The digestion solution was then loaded onto a 1% agarose gel for
electrophoresis. The restriction pattern was compared to the map of the construct to
determine which digested plasmid DNA contains DNA fragments of expected sizes {see
Figure 8). The digestion pattern also verifies that the insertion of cDNAs are of the
correct orientation in both plasmids.
The plasmid DNA with the correct restriction pattern was then subjected to DNA
sequencing for further verification.
c) DNA sequencing
The sequencing was performed using Primer-3/Primer-4 for pLNCX-gdnf-ruc and
Primer-9/Primer-10 for pLNCX-sruc-gdnf {see Table 3), by an automated DNA
sequencer at the CMBGT Core Facility of Loma Linda University. Sequence analysis
was focused on the fusion region of both constructs, that is, the 3’ region of RUC, the
linker region, and the 5’ region of GDNF on pLNCX-sruc-gdnf, or the 3’ portion of
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Figure 8. Confirmation of constructs by digestion and electrophoresis
pLNCX-sruc-gdnf was digested with Hind Ill/Xho I, and Sal I.
pLNCX-gdnf-ruc was digested with Hind III/EcoR I and BamH I.
The digestion pattern is:
pLNCX-sruc-gdnf: 3.6 kb, 3.0 kb, 0.9 kb, and 0.6 kb {HindIll/Xho 7, and Sal I).
pLNCX-gdnf-ruc: 3.6 kb, 3.0 kb, 0.9 kb, 0.3 kb, 0.4 kb {HindIII/EcoR I),
6 kb, 2.6 kb {BamHI).
Lane 1: DNA 1 kb marker.
Lane 2: DNA 100 bp marker.
Lane 3 pLNCX-gdnf-ruc plasmid DNA by Hind III/EcoR I
Lane 4: pLNCX-sruc-gdnf plasmid DNA by Hind Ill/Xho I, and Sal I.
Lane 5: pLNCX-gdnf-ruc plasmid DNA by BamH I.
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GDNF, the linker region, and the 5’ portion of RUC on pLNCX-gdnf-ruc. The amino
acid sequence was deduced from the fusion region to ensure in-frame translation.
2. Establishment of fusion DNA transformed cell lines
To introduce the plasmid DNA which carries the fusion gene into mammalian
cells, transfection was performed in multiple cell lines, including COS-7, NIH/3T3, PC12, TH-133, and PO-D17. Cells were transfected and the one with highest transfection
efficiency and secretion of the fusion protein was selected for further studies.
Plasmid DNA of pLNCX-sruc-gdnf, pLNCX-gdnf-ruc and pLNCX (as a mock
control) were used. Plasmid DNA of pLNCX-puro was used with a 1:1 molecular ratio
to the fusion constructs or pLNCX, to select transformants. Puromycin must be used to
select for stable transformant because PO-D17 cells were already transfected with Neor
during the immortalization.
1) Transient transfection of mammalian cells
Lipofection was performed for transfection using FuGENE 6 Transfection
Reagent (Roche). This is a multi-component lipid-based transfection reagent that
complexes with and transports DNA into cells during transfection. The plasmid DNA
constructs were prepared with a QIAfilter Midiprep Kit, and dissolved in sterile
deionized water at a concentration of 1 pg/pl.
PO-D17 Cells were plated one day before the transfection experiment. The
plating density was about 1-3 x 106 cells in 3 ml media in a 60 mm culture dish so that
the culture was approximately 50-60% confluent after overnight incubation. The cells
were grown in DMEM medium supplemented with 10% FBS under a 5% CO2
atmosphere at 37°C.
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About 6 \x\ of FuGENE 6 Reagent were used for 2 jag of DNA. For transfection
of cells on a 60 mm plate, 94 pi of serum-free medium was pipetted into a 1.5-ml sterile
microcentrifuge tube as diluent, and then 6 pi of FuGENE 6 Reagent was added directly
into this medium, mixed by gently tapping. A total of 2 pg of pLNCX-puro and one of
the constructs, pLNCX-sruc-gdnf, pLNCX-gdnf-ruc, or pLNCX , with equal molar
concentration was added to the tube, and mixed gently. The complex mixture was
incubated at room temperature for a minimum of 15 minutes before adding it dropwise to
the cells. The plates were then swirled to ensure even dispersal, followed by incubation
at 37°C. Multiple plates of cells were transfected each time so that the expression levels
could be determined at various time points after transfection.
3. Verification of GDNF and RUG presence in the fusion protein
The presence of two proteins in the fusion form of the new protein is
demonstrated at two layers: structural, and functional. Verification of structural integrity
was done through Western blotting where antibodies were applied to the sample to see if
the fusion protein could be recognized by the specific antibodies. Verification of
functional integrity was through RUC and GDNF bioactivity assays.
1) RUC bioassay and spectral analysis of luminescence
RUC bioassay was performed to measure the activity of RUC in the fusion
protein. The activity was measured by the light emitted (470 nm) from the enzymatic
reaction by mixing the sample with RUC substrate, coelecterazine.
To obtain the culture medium sample and cell lysate sample, transfected cells
were grown to monolayer in DMEM supplemented with fetal bovine serum. Cells were
then gently washed twice with ice-cold PBS and changed to serum-free DMEM and
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incubated for 24 hours. To harvest medium and cells, plates were removed from the
incubator and placed on crushed ice. The culture medium of 10 ml was collected by
centrifugation at 600xg for 5 minutes at 4°C to pellet the residual cells.
The attached cells were washed twice with ice-cold PBS, and the last traces of
PBS were drained from the plate. About 0.5 ml of ice-cold lysis buffer (single-detergent
lysis buffer) was applied to the cell monolayer in a 10-cm plate. The plate was incubated
on ice for 20 minutes before the cell layer was scraped off with a rubber policeman. The
cell suspension in the lysis buffer was transferred to a chilled microcentrifuge tube and
sonicated to homogenize. The homogenate was centrifuged at 12,000xg for 2 minutes at
4°C. The supernatant was removed and transferred to a fresh microfuge tube and added
RUC assay buffer to 1ml. Tubes were stored at -70°C until analysis.
An aliquot of 100 pi (1% of total volume of 10 ml) culture medium or 10 pi (1%
of total volume of 1 ml) cell lysate was then added to 100 pi RUC assay buffer. To the
culture medium sample or cell lysate sample was then added 100 pi of 1 pM
coelenterazine and the light emission was measured immediately using Hamamatsu
Argus-100 low-light imaging system and Turner TD-20e luminometer. Luminometer
data were used to calibrate the Hamamatsu and verify the accuracy of the low-light
imager.
The spectrum of light emission was obtained by the use of a FluoroMax-3
spectrofluorometer, to further verify that the light emitted from the reaction has indeed
the characteristic wavelength of Renilla luciferase catalyzed reactions. Approximately
7x106 transfected cells were scraped off of the 10-cm petridish and resuspended in 50 pi
RUC assay buffer, then mixed with 50 pi 1 pM coelenterazine. The mixture was
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immediately loaded onto the FuoroMax-3 spectrofluorometer and the wavelength of light
emission was detected and compared to the standard RUC positive control, of which the
wavelength is 470 nm.
2) Western blotting
Western blotting was performed to 1) ensure that the fusion proteins are
recognized by the antibodies; and 2) determine the molecular weight of the fusion
proteins secreted from the transfected mammalian cells.
The culture medium prepared as previously described, was concentrated 100 fold
by filtration through an Amicon Centriplus concentrator- 100 and was stored at
-70°C till analysis. This was necessary because previous data showed that the
concentration of GDNF was insufficient for Western blotting.
Thirty pi of concentrated culture medium was mixed with an equal volume of 2x
SDS gel loading buffer, and boiled at 100°C for 3 minutes before separation by SDSPAGE. The SDS-PAGE was performed on a 12% separating gel using a 5% stacking
gel. The electrophoresis was carried out at constant voltage of 40 V in the stacking gel
and at 80 V in the separating gel.
The Opti-4CN Detection Kit (Goat-anti-Rabbit) from BioRad was used in
Western blotting according to manufacturer’s instructions. After electrophoresis, the
proteins were transferred onto a nitrocellulose membrane by electro blotting using the
BioRad semi-dry blotting system. Once the transfer was complete, the membranes were
rinsed in lx PBST, twice for 5 minutes each. The membranes were incubated with the
blocking solution for at least one hour (or overnight at 4°C). The membranes were
washed in PBST twice before subjecting them to primary antibody polyclonal anti-RUC
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(rabbit), or polyclonal anti-GDNF (chicken). The primary antibody was diluted 5000
fold with an antibody dilution buffer and the incubation was carried out for 1 hour with
gentle shaking on a rocking platform. An additional two washes were applied before
incubation with a 3000-fold dilution of the secondary antibody, the horseradish
peroxidase conjugated goat-anti-rabbit antibody (HRP-GAR) for RUC, or horseradish
peroxidase conjugated anti-chicken IgY (Promega). After 1 hour of incubation with the
secondary antibody, the membranes were washed twice with PBST, and the Opti-4CN
substrate was applied for color development. The membranes were photographed after
the color developed to the desired intensity.
3) GDNF bioassay
Activity of GDNF can be tested in several ways: 1) by protecting dopaminergic
cells against neurotoxtins such as 6-hydroxyldopamine; 2) by stimulating dopa reuptake;
or 3) by promoting neurite outgrowth. In this study, the neurite outgrowth promoting
property of GDNF was used.
The bioassay was performed using near-term sheep dorsal root ganglion (DRG)
cell cultures. DRG has been used to demonstrate the survival effects of GDNF on
tyrosine hydroxylase positive cells, which include dopaminergic cells, because these cells
have developed GDNF receptors (RET, GFRalpha-1, and GFRalpha-2) (Trupp et al.
1995; Hammarberg et al. 1996; Matheson et al. 1997; Molliver et al. 1997; Bar et al.
1998; Bennett et al. 1998; Kashiba et al. 1998; Honda et al. 1999). The length of DRG
neurite was the measure of GDNF activity.
a) Harvest of DRG cells
The protocol for harvesting dorsal root ganglion cells was adopted and modified
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from the protocol developed in the laboratory of Dr. John Buchholz of Loma Linda
University to harvest superior cervical ganglion cells.
Five dorsal root ganglia or superior cervical ganglia were dissected from lumbar
segments of the spinal cord and the cells were dissociated by incubation in 10 ml of
digestion buffer (DMEM, lx antibiotics, 10 mg/ml trypsin, 2.2 mg/ml DNAse, 2 mg/ml
collagenase D) for 4 hours at 37°C with intermittent mixing. The cell pellet was collected
by centrifugation at 600xg for 5 minutes at 4°C, re-suspended in DMEM with lx
antibiotics solution and the cells were placed onto a 10-cm tissue culture dish. The
culture medium was aspirated after incubation for 4 hours at 37°C under 5% CO2. Cells
attached to the dish surface were discarded since most of these cells are non-neuron cells.
Non-attached cells in the aspirated medium were then centrifuged down, replaced in
DMEM with 10% fetal bovine serum, followed by incubation for 8 hours or until all cells
were attached to the plate. The DRG cell culture was then treated as follows:
b) Treatment of DRG with fusion protein
After washing twice with ice-cold PBS, DRG cell cultures were treated with 1 ml
of one of the three extracts:
•

Purified Renilla luciferase dissolved in DMEM (control, med-ruc)

•

The medium of cells transfected with pLNCX-sruc-gdnf (med-rgl)

•

The medium from cells stably transfected with pLNCX vector as MOCK
control (control, med-mock)

The concentrations of med-ruc and med-rgl in the treatment culture medium were
standardized by light emission. The concentration of med-mock in the treatment culture
medium was normalized by its total protein equal to that of med-rgl. The cells were
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treated for up to 72 hours. No serum or supplemental protein factors were added to the
treatment solution, to ensure that no growth factors were present in the culture medium
prior to treatment.
c) Measurement of DRG neurite outgrowth
Light microscopic images were taken after 72 hours of treatment when neurite
outgrowth reached a maximum with default nutrient. The neurite outgrowth was defined
as mature if the length of neurite was at least twice of that of the cell body.
4) Correlation of RUC activity with GDNF ELISA
In order to establish the correlations between RUC activity and GDNF
concentration, ELISA was performed to determine the concentration of GDNF in RG-1
culture medium. Establishing this correlation is to ensure that RUC activity measurement
can accurately report GDNF production, since RUC and GDNF are expressed as a single
protein under the control of a single promoter and transcriptional factor. There are
possibilities that RUC and GDNF, once translated and secreted as a single poly-peptide
chain, could be cleaved and separated into two proteins, however ELISA should still
show that the correlation between RUC activity and GDNF concentration is linear.
The ideal testimony of RUC and GDNF correlation would be a correlation
between molar concentrations determined by ELISA using both antibodies against RUC
and GDNF. Unfortunately, the RUC antibody available failed to recognize the RUCGDNF fusion proteins, as demonstrated by Western blotting. Therefore, only GDNF
concentration was determined by ELISA.
The procedure was based on the GDNF Emax Immunoassay System (Promega)
and carried out per manufacturer’s instructions. Briefly, the 96-well plate was coated
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with anti-GDNF mAh antibody overnight at 4°C. The plate was then blocked with Block
& Sample buffer. GDNF standard was 1:2 serially diluted by Block & Sample buffer and
loaded to the wells as 1000 pg/ml, 500 pg/ml, 250 pg/ml, 125 pg/ml, 62 pg/ml, 31 pg/ml,
15 pg/ml, 8 pg/ml, 4 pg/ml, 2 pg/ml, and 0 pg/ml. The samples (RG-1 culture medium,
non-concentrated) were also loaded to the wells as 1:2 serial dilutions with a starting
sample loading volume of 100 pi. This volume was determined by measuring the
maximum light emission within the working range of the low-light imager. After
incubation, the plate was washed with PBST, and anti-human GDNF pAb was added,
followed by addition of HRP conjugated anti-chicken IgY. The color development was
achieved by addition of TMB solution and peroxidase substrate to the wells. The reaction
was stopped by adding 1M phosphoric acid to the wells. Absorbance at 450 nm was
recorded on a plate reader.
The same volume of sample was used to measure for RUG activity. Correlation
and regression analysis were then performed using SPSS for RUG activity (by photon
counting) and GDNF quantification by ELISA.
4. Establishment of stable mammalian cell lines
Stable mammalian cell lines based on transiently transfected PO-D17, were
constructed by puromycin selection, since during the previous transient transfection
stage, puror gene was introduced to cells by pLNCX-puro transfection. Furthermore,
puromycin selection offers maximum selection within a much shorter period of time,
compared to other commonly used selectors.
1) Drug selection for permanently transfected cells
Cells transfected with pLNCX-sruc-gdnf, pLNCX-gdnf-ruc, and pLNCX were
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also co-transfected with pLNCX-puro (see transient transfection) by exposure to
puromycin. Cells that acquired puror survived the exposure, while those that did not
acquire puror were lysed by puromycin. It has been an empirical observation by
numerous groups that mammalian cell can acquire multiple plasmids during the
lipofection process. We expectated therefore that both pLNCX-puro and the other
plasmid (pLNCX-sruc-gdnf, pLNCX-gdnf-ruc, or pLNCX) could be taken up by the
cells, hence both the fusion protein genes and puror gene could be introduced into the
cells.
The selection pressure can be gradually increased to select those that acquired
more copies of puror gene. The more copies of the plasmid DNA, the higher the selection
pressure that can be used. In this study, 5 pg/ml was set to be the maximum selection
pressure of puromycin. While this pressure could be higher, the pressure used in this
study was determined purely by the time allotted to this project.
The initial selection concentration of puromycin was 1 pg/ml. Two pi of
puromycin stock solution of 5 pg/pl was added to the 10-cm petridish, or 0.3 pi to the 6cm dish with standard culture medium of DMEM supplemented with 10% FBS,
approximately 72 hours after initial transfection. The medium was replaced by fresh
DMEM/FBS with 1.5 pl/ml puromycin 48 hours later, then 2.0 pl/ml 96 hours later. At
day 6 after selection, single clones of cells were then transferred to 24-well tissue culture
plate for further selection.
To transfer single clones to new plate, culture medium was removed and a sterile
lead ring (diameter 5 mm) was carefully glued by sterile silicon gel to surround the single
clone. Twenty pi of Trypsin/EDTA (lx) was immediately applied into the ring to
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disassociate the cells. After incubation for 3 minutes, the trypsinized cells inside the ring
was then aspirated and transferred to the 24-well plate with 1 ml of DMEM/FBS in each
well.
The concentration of puromycin was gradually increased by 0.5 pg/ml per 48
hours to the cells in the 24-well plate, until 5 pg/ml was reached and maintained. Cells
were then trypsinized and transferred to 10-cm petri dish with DMEM/FBS and 5 pl/ml
puromycin. With the maintenance dose of puromycin of 5 pg/ml, medium was collected
to measure RUC activity. The pLNCX-sruc-gdnf transfected clone that displayed the
highest RUC activity in medium was chosen for stereotactic implantation and named as
RG-1 and the pLNCX-gdnf-ruc transfected clone that displayed the highest RUC activity
intracellularly was named GR-1. All following experiments are based on permanently
transfected cells.
2) Confirmation of the RG fusion in host genome by PCR
To confirm that the RUC-GDNF fusion gene has integrated into the host (RG-1)
genome, PCR was performed on the host genomic DNA. Only RG-1 was examined for
integration because it produced secretive fusion protein, hence chosen for further study.
The rationale is that if the RUC-GDNF fusion gene was integrated into the genome, PCR
with primers designed based on 5’ of RUC and 3’ of GDNF cDNA would yield a product
of 1.6 kb (RUC+GDNF), of which the sequence would match that of the RUC-GDNF
fusion gene. If the fusion gene did not integrate into the host genome, then genomic
DNA would not yield a PCR product with the expected size of 1.6 kb. The RUC gene
can be primed because the mammalian cell genome does not contain the conserved RUC
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gene, however it does contain the GDNF gene. Use of both RUC and GDNF primers
permits only the RUC-GDNF fusion gene to be primed.
a. Isolation of Genomic DNA
This method was adapted from Sambrook’s Molecular Cloning, A Laboratory
Manual: Isolation of DNA from Mammalian Cells (Protocol I). Transfected cells (RG-1)
were washed twice with ice-cold PBS and scraped off the plate in 0.5 ml of extraction
buffer and placed in a 2-ml centrifuge tube. The tube was incubated for 1 hour at 37°C,
and then proteinase K was added to a final concentration of 100 pg/ml. The tube was
placed in a 50°C water bath for 3 hours with periodic swirling. The solution was then
cooled down to room temperature, and an equal volume of phenol (equilibrated with 0.5
M Tris-HCl pH 8.0) was added. The tube was turned slowly to allow the two phases to
form an emulsion. The separation of the two phases was achieved by centrifugation at
5,000g for 15 minutes at room temperature.
The viscous upper, aqueous phase was transferred with a wide-bore pipette to a
clean centrifuge tube, and the extraction with phenol was repeated twice. After the third
extraction, the aqueous phase was transferred to a fresh centrifuge tube and 0.2 volume of
10 M ammonium acetate and 2 volumes of ethanol (room temperature) were added.
When the solution was thoroughly mixed, the DNA precipitate was immediately formed,
and was removed from the ethanolic solution with a U-shaped Pasteur pipette. The DNA
was dissolved in TE buffer, and the concentration of the DNA was determined by OD260The DNA samples were stored at 4°C.
Genomic DNA from MOCK transfected cells was also extracted as a negative
control for PGR analysis.
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b. PCR amplification of genomic DNA with specific primers
Genomic DNA extracted from RG-1 was used as the template in PCR reactions.
Primer-7 (5’ of RUG) and primer-4 (3’ of GDNF) {see Table 3) were used as the forward
and reverse primers. The setting for the PCR program is presented in Table 4.
c. Sequence confirmation of cDNA integration
The PCR product was sequenced with Primer-9 (Table 3), covering the 3’ end of
the RUC cDNA, the linker region and the 5’ end of the GDNF cDNA. The sequence was
then compared against the theoretical sequence of the RUC-GDNF fusion gene, and
against known genes at 50% contingency using the BLAST program at
www.ncbi.nlm.nih.gov.
3) Time course of RUC activity in RG-1 medium
The time-course study was performed to measure the stability of RG-1 in terms of
RUC activity of the RUC-GDNF fusion protein. GR-1 and stable mock transfected cells
were used as the negative control.
After puromycin selection pressure reached 5 pg/ml, the RUC bioassay was
performed at 24 hours, 48 hours, 72 hours, 1 week, and 2 months in the culture medium,
after cells were passaged by trypsinization. For each time point, 4 10-cm plates of cells
from the same RG-1 origin were sampled, with 100 pi from each plate. The RUC assay
procedure was as previously described. Since the RUC assay varies with the degree of
confluency, light emission readings were used to standardize the approximate number of
cells in the culture.
5. Stereotactic implantation and monitoring of GDNF secretion in CSF
Once the RG-1 cells were characterized in culture, the cells were then used for
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cellular implantation in animals. It was expected that the implanted cells would express
and secrete the RUG-GDNF fusion protein into the brain matrix, and diffuse into the
lateral ventricle and enter the cerebrospinal fluid (CSF) circulation. The RUC assay in
CSF would thus enable the monitoring of GDNF production in the form of RUC-GDNF.
Adult male Sprague-Dawley rats of approximately 200 g body weight were used.
Rodents were housed in individual rodent cage with rodent food and water supplied until
12 hours prior to surgery.
RG-1 cells were delivered to the brain of the animals and at a certain time point,
CSF was aspirated and analyzed for RUC activity and the time course of RUC activity
was established. The brain region where the cells were implanted was then examined for
RUC activity to establish the correlation between CSF and loci of implantation.
1) Implantation of RG-1
The target for the implantation and injection of GDNF is caudate-putamen, which
has been used in several studies (Aebischer et al. 1994; Emerich et al. 1996; Cheng et al.
1998), as this is the target of dopaminergic innervation and highest expression of GDNF
(Schaar e? <2/. 1994).
The coordinates for the target are 1) anterior-posterior axis: 0.8mm posterior to
Bregma; 2) lateral: 2.5 mm to the midline; 3) dorsal-ventral axis: 4.5 mm {see Figure 9).
The stereotactic neurosurgery setting is shown in Figure 10.
The animal was anesthetized with 1% halothane. It was then immobilized onto
the stereotactic head frame by bite bar and ear bars. After sterilizing with Betadine and
injection of local anesthetics 5% bupivacaine & epinephrine, the skin was then cut by 10
mm to expose the landmarks, Bregma and Lambda. Lambda was used to confirm the
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Figure 9. Stereotactic implantation: targeting.
Caudate is the target of cellular implantation, cistern is the source of CSF. Ticks are in
mm. Arrows indicate trajectory of needle and diffusion of the cellular product. The dot
indicates the target (Caudate). The dark region is lateral ventricles and third ventricle.
The enclosed diagram shows the location of the cistern.
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precision positioning of Bregma. The position of Bregma was used as the reference as
“0”. The coordinates for Caudate in reference to Bregma and midline are: Anteriorposterior: 0.8 mm posterior to Bregma; Lateral: 3.0 mm lateral to midline; Dorsal-ventral
(depth): 4.5 mm. After drilling a surgical hole of 2 x 2 mm in diameter, at the anteriorposterior and lateral coordinates, a 26S gauge Hamilton needle attached to 10 pi
Hamilton syringe, both sterilized with 70% ethanol and sterilized water and loaded with
approximately 1x106 RG-1 cells suspended in 10 pi DMEM, was then placed over the
surgical hole with its tip touching the outer surface of dura mater. With dura mater as
the 0 reference to the dorsal-ventral coordinate, the needle was then slowly lowered to the
target defined by the dorsal-ventral axis. The cell suspension was then injected to the
target at a speed of 0.5 pl/minute. After injection was completed, the needle was slowly
withdrawn and the surgical wound closed by suture. The skin was then sterilized with
Betadine again and the animal was closely monitored for vital signs and returned to its
individual cage after awakening. Animals were fed with rodent food and water ad lib
after surgery.
2) Extraction of CSF
Before and after cellular implantation, cisternal CSF was drawn from the cistern.
The animal was immobilized and anesthetized the same way as in cellular implantation.
The skin at the cistema magna was sterilized with Betadine, and a 26(s) gauge Hamilton
needle attached to 20 pi Hamilton syringe , both sterilized with 70% ethanol and
sterilized water, were used to extract cisternal CSF. The needle was positioned 45° along
the midline with the bevel facing the posterior. It was then lowered by 7-8 mm in depth
until the penetration of the dura mater was felt by hand. Up to 15 pi CSF was aspirated
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and immediately place on ice and stored at -70°C until analyzed. Extreme caution was
exercised when inserting the needle to avoid disrupting cardiovascular and respiratory
regulation centers in the medulla on the base of the cistern.
Multiple cisternal CSF samplings were performed using same procedure at 24 hour; 2-day; 3-day; 5-day; 10-day; 15-day, 20-day, and 25-day post implantation.
3) RUC bioassay on retrieved CSF
The RUC assay was performed on 10 pi cisternal CSF collected at different time
points, using the same procedure described previously. Exposure time was increased to
10 minutes, instead of 3 minutes in culture medium samples, due to very low light
emission.
4) GDNF bioassay, ELISA, and Western blotting of cisternal CSF
These procedures were performed in 5 (per procedure) post-implantation day-3
CSF specimens that had been determined to have high RUC activity in the preliminary
experiment, using the same procedure described previously. The sample size for each
procedure is 10 pi.
For GDNF bioassay, the minimum volume of treatment solution is 100 pi by
addition of DMEM for DRG cell culture. Therefore CSF must be diluted by 10-fold.
For ELISA and Western blotting, the loading volume of CSF was 10 pi.
5) Brain tissue analysis
Hemibrain tissue was used to assay for RUC, to determine the fate of implanted
cells over the long-term (1.5 month). Since cells might be exposed to the host immune
reaction and be rejected after implantation, CSF RUC activity might decline to a certain
level that is beyond detection. However the whole brain may still have residual
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implanted cells and these may survive the initial immune rejection and adapt to the host
environment, and revival of implanted cells may be expected. Data from this study can
be used to guide future studies towards optimization of the mammalian cell lines.
At various intervals after implantation, the animals were sacrificed by overdosing
with 30 mg Nembutal and whole brain was removed and flash frozen in 2-methylbutane
in dry ice. The frozen brain was then stored in -70°C until analyzed for RUC activity.
The hemibrain was then ground in liquid nitrogen, with the implanted side and the
contralateral side separated. Ground raw tissue was then further homogenized by hand in
100 pi RUC assay buffer. The homogenate was added 100 pi 1 pM coelecterazine and
the luminescence was measured by the Hamamatsu low-light imager. RUC activities of
the hemibrain of implanted and contralateral sides were compared, and the brains at
different time-point were compared.
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CHAPTER III. RESULTS AND DISCUSSIONS
A. Renilla Luciferase Reported GDNF Production in vitro
1. Properties of the fusion constructs
The vector pLNCX-sruc-gdnf {see Figure 6C) contains a CMV promoter
immediately upstream to the multiple cloning sites. The human interleukin-2 signal
peptide was fused to the N-terminus of RUC cDNA. The rat GDNF cDNA was fused to
the C-terminus of RUC cDNA via a 9bp linker. The stop codon of RUC and the signal
peptide sequence of GDNF were excised.
The vector pLNCX-gdnf-ruc structure {see Figure 6D) is similar to pLNCX-srucgdnf, except that its signal peptide sequence is the intrinsic sequence of GDNF, and
GDNF cDNA is placed 5’ to the N-terminus of RUC cDNA, with the GDNF stop codon
removed.
1) Digestions
As shown in Figure 8, digestion of pLNCX-sruc-gdnf with restriction enzymes
Hind III, Xho I, and Sal I revealed distinctive bands with size matching the predicted
digestion pattern based on map of pLNCX-sruc-gdnf (Figure 6C).
Digestion of pLNCX-gdnf-ruc with Hind III/EcoR I and item// / enzymes also
revealed expected bands matching the predicted pattern for pLNCX-gdnf-ruc (Figure
6D).
Digestion of pLNCX-puro with Hind III and Cla / revealed a band at 660 bp,
confirming the insertion of puror sequence in pLNCX .
2) Fusion construct was integrated into the genome of transfected cells
Figure 11 shows the partial sequence of the PCR product amplified from RG-1
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host genome which contains RUC and GDNF sequences. This indicates that the RUCGDNF fusion gene has integrated into the host genome. Stable expression of the fusion
protein is thus expected in the RG-1 cell line.
Furthermore, partial sequence of pLNCX-sruc-gdnf and pLNCX-gdnf-ruc
revealed in-frame sequence of the C-terminal regions of RUC or GDNF and the linker
region, ensuring the in-frame translation of the downstream peptide. While sequence of
pLNCX-gdnf-ruc (not shown) matches that of the published sequence of RUC and GDNF
and the predicted linker sequence, pLNCX-sruc-gdnf does contain several point
mutations in the C-terminal region of RUC and the linker region (Figure 11), although
these mutations did not result in an out-of-frame sequence.
Spontaneous mutations do occur during the process of transfection (Bourre et al.
1991; Madzak et al. 1992; Hauser et al 1987; Lebkowski et al. 1984). It seems to be
related to the error-repair mechanism, induction by chemicals, type of vectors and
mammalian cells. Since the mutations do not seem to cause frame-shift, no attempts have
been made to determine the factors involved in the mutagenesis. In frame translation of
pLNCX-sruc-gdnf is also supported by Western blotting analysis, which shows the fusion
protein can be recognized by anti-GDNF antibody as presented in the next section.
Lastly, the fusion protein also retains both RUC and GDNF activities, therefore no
attempts have been made to correct the errors.
2. Properties of the fusion protein
1) Molecular weight of fusion protein was confirmed
The molecular weight of the fusion protein is between 70 and 75 kD as
determined by Western blotting using polyclonal antibodies against GDNF (Figure 12),
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Figure 11. Host genome sequencing of the insert from pLNCX-ruc-gdnf transfected cells
(RG-1).
Three deletions are shown in the obtained sequence. Although in-frame translation of
GDNF is not affected, the C-terminus of RUC is frame-shifted into a new amino acid
sequence.
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Predicted sequence of pLNCX-sruc-gdnf
.AATGGGAAATATATCAAATCGTTCGTTGAGCGATGTCTCAAA
AATGAACAAGCTCGAGAATTCCCGCTGCCCGCCGGTAAGAGG,

Obtained sequence of pLNCX-sruc-gdnf
.AATGGGAAATATATCAAATCGTTCGTTGAGCGATGTCTCAAA
AATGAACAAGCTCGAGAATTCCCGCTGCCCGCCGGTAAGAGG,

single underline: RUC C-terminal sequence
double underline: GDNF N-terminal sequence
grey color: single base deletion
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Figure 12. Western blot of total proteins secreted into the culture medium.
The sample is serum-free medium of RG-1 cells grown at 100% confluency. Anti-RUC
mAh was applied in the left panel, anti-GDNF pAb applied in the right panel. Purified
RUG enzyme shows a molecular weight of about 35 kD, GDNF approximately 33 kD.
Fusion protein recognized by GDNF antibody has the molecular weight of approximately
72 kD, while RUG antibody failed to recognize the fusion protein. The separating gel is
12% acrylamide. Loading volume of 100-fold concentrated serum-free culture medium
is 30 pi.
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suggesting the correct size of the fusion protein (RUC 35 kD, GDNF ~32 kD) with
glycosalation.
To our surprise, unlike the purified Renilla luciferase control, the fusion protein
which clearly possesses RUC activity, was not recognized by the anti-RUC antibody.
Although it can be expected that the epitopes against which an antibody was raised
remain intact when the catalytic units of an enzyme remain active, they may not always
be available to the antibody if the folding of the protein does not permit the exposure of
the epitopes. Conformational change of the RUC portion by the fusion of GDNF may
hinder the binding of the antibody to the epitopes.
The size of the fusion protein has been clearly indicated by the binding of fusion
protein with anti-GDNF antibody. Since no smaller bands can be identified by GDNF
antibody, it is likely GDNF and RUC are not separated by cleavage upon secretion.
2) RUC and GDNF bioactivities are retained in fusion protein
Upon transfection of mammalian cells with the fusion construct, luciferase
activity was detected in the cells as well as in the culture medium following the addition
of coelecterazine (Figure 13). The spectrum of light emission in the cell lysate of RG-1
is 472 nm, matching the wavelength of purified RUC protein (Figure 14).
GDNF bioactivity of the fusion protein was confirmed by the fetal sheep dorsal
root ganglion assay which resulted in distinct stimulation of neurite outgrowth in vitro
(Figure 15).
DRG cells are TH+ cells and have been commonly used as the culture model to
test for GDNF activity, because these cells express GDNF receptors identified so far,
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Figure 13. Localization of luciferase activity in cultures of secreting and non-secreting
cell lines.
The image shows the RUC assay in medium and cell lysate after 72 hours of confluent
culture. Data clearly show that RUC-GDNF fusion is secreted, and that GDNF-RUC is
not secreted.
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Figure 14. Light emission spectra of RUC-GDNF fusion proteins.
The spectrum of light emission from RG-1 cell is 472 nm (marked with dotted line), the
same as that of purified RUC (lower scan). This indicates that the light emission of the
reaction is indeed from RUC in the form of RUC-GDNF.
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Figure 15. GDNF bioassay using sheep DRG..
DRG cultures were treated with the following three medium for 72 hours. Images are
from the light microscope at 3OX. Neurites are denoted by the arrow. DRG neurite
outgrowth reflects the degree of neuronal maturity. A matured neuron is defined as
neurite outgrowth length at least twice that of the cell body.
Compared to negative controls, mock transfectant medium and purified RUC, only the
RG-1 medium significantly promoted neurite outgrowth. Volume of treatment medium is
1 ml per well on the 24-well plate.
A. Morphology of treated DRG cells
B. Count of mature DRG cells after treatment
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namely, RET, GFRalpha-1, and GFRalpha-2 (Molliver et al. 1997; Bennett et al. 1998;
Kashiba et al. 1998). The dopaminergic cell selective neurotoxin, 6-hydroxydopamine
(6-OHDA) could also be used to test for GDNF survival effect. However, since
morphological changes of DRG neurons upon treatment of RG-1 medium are clear,
further confirmation with TH immunocytochemical staining is not necessary.
3) Fusion protein secretion from RG-1 and GR-1
The levels of light emission from tested cells vary. Among all cell lines tested,
PO-D17 cells yielded highest levels of light emission in culture medium of transient
transformants, therefore this cell line was chosen as the vehicle cell line, named RG-1 in
future implantation studies. High levels of RUC activity in medium and low levels in cell
lysate indicate the high degree of secretion of the fusion protein and is the desired
property of the candidate cell line for gene therapy applications. As shown in Figure 13,
RG-1 culture exhibits a high RUC secretion pattern, while GR-1 culture does not.
There is no plausible explanation for the low levels of secretion in GR-1 cells.
Hydropathy analysis on the amino acid sequence of the fusion proteins was performed
using Omiga 2.1. Both RUC-GDNF and GDNF-RUC were predicted as soluble proteins
(Figure 16), since the hydrophobicity rich region is localized to the signal peptide.
Since the secretion of GDNF-RUC fusion protein is facilitated by the signal
peptide of GDNF, the little secretion might be due to the strength of the signal peptide. If
the signal peptide cannot be recognized and cleaved off of the polypeptide, the protein
would be trapped on the plasmic membrane and not secreted. It is also possible that
GDNF-RUC fusion protein might aggregate to form particles that exceed the transporter
capability of the cell membrane.
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Figure 16. Hydropathy analysis of fusion proteins based on their amino acid sequence.
The predicted hydropathy of both RUC-GDNF and GDNF-RUC fusion proteins shows
only the signal peptide as the hydrophobic region, therefore both proteins are likely to be
soluble and secreted.
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4) Correlation of RUC activity and GDNF quantification using ELISA
The concentration of GDNF in culture medium was determined by ELISA assay,
which correlates with photon counting of the RUC bioassay measured in the Hamamatsu
Argus-100 low-light imager. Figure 17 shows that the correlation coefficient is 0.95 with
p < 0.01, suggesting that luciferase activity in the culture medium reliably reflects the
concentration of GDNF in the same culture.
The regression equation is GDNF (pg/ml) = 0.0005 x (photon/ml)

0.7883

. R square

is 0.93, which means that 93% of the variance in GDNF concentration is due to RUC
photon reading. According to this equation, 30 pi of 100-fold concentrated culture
medium supernatant used in Western blotting (see Figure 12) contains approximately 1.4
ng GDNF with a photon counting of approximately 1.5xl08 based on the time course
result.
Apparently the relationship between RUC photon counting and GDNF
concentration by ELISA is non-linear, however it does assume linear correlation at either
the low or high range of photon readings. The reason for this is likely due to the non
linearity of the photon counting by the Hamamatsu Argus-100, which has a narrow
linearity range.
3. Properties of RG-1 and GR-1 cell lines
1) Morphology, growth rate, and contact inhibition
In DMEM supplemented with 10% FBS, the RG-1 cell line doubling time is about
48 hours, which is not different from the non-transfected parental cells. Morphology and
growth rate remain stable in this medium. Contact inhibition is retained but reduced
compared to the non-transfected native state. On the contrary, GR-1 cells lost contact
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Figure 17. ELISA of GDNF correlates with RUC activity.
RUC activity is shown as photon count per ml. GDNF amount is shown in pg/ml.
Volume is equalized. The correlation between photon counts and GDNF amount does
not assume a linear relationship. The explanation might be that the photon counts exceed
the linear range of the low-light imaging system.
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inhibition almost completely. The RG-1 remain viable and functional in terms of RUCGDNF fusion secretion for at least 2 weeks in a completely confluent monolayer,
compared to 2 months in the native state, and 2 days in the GR-1 cells. Viability and
functionality are retained for as long as full confluency is avoided by intermittent
passaging of cells during the 2-month observation period.
Contact inhibition is a desired property of cells for implantation, simply because
immortalized cells can grow into tumors once implanted. Contact inhibition is also
desired if encapsulation is to be used in implantation to protect implanted cells against
host immune rejection, since currently used polymer microcapsules might rupture under
the circumstance of cell overgrowth (Leu et al. 1992; Matthew et al. 1993). To prevent
cell overgrowth, the introduction of an inducible promoter that can act as a “death
switch” to the implanted cells may be necessary. The apoptosis cascade can be induced
by switching on this promoter, so that the number of implanted cells can be maintained at
the therapeutic “dose”.
2) Time course of the secretion of RUC-GDNF fusion protein
As shown in Figure 18, permanently transfected RG-1 cells produce and secrete
the RUC-GDNF fusion protein at a constant rate during the entire 2 month period of
observation. In contrast, the GR-1 cells produce but do not secrete the GDNF-RUC
fusion protein. Under the maintenance dose of puromycin of 5 pg/ml in culture, no
decline of RUC-GDNF secretion was found in RG-1. Also revealed in Figure 18 is the
relatively small variability between RG-1 sibling cultures (homogeneity test of 72-hour
RUC reading in medium is non-significant, with p = 0.115), reflecting the homogeneity
and stability of this cell line in terms of RUC-GDNF production. RUC activity reading in
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Figure 18. Time-course of RUC-GDNF production from RG-1 cell culture.
The graph shows time course of RUC activity in culture medium of RG-1 (•), GR-1 (o, a
cell line transfected with a construct that contains the GDNF-RUC fusion), and a MOCK
transfectant as a control(a). Loading volume of culture medium 100 pi. Exposure time is
3 minutes.
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RG-1 maintained at 5xl06 photons/3 min/100 pi level (n - 4, SD - 1.2xl05) during the 2month observation.
Driven by the constitutively expressed CMV promoter, the RUC-GDNF
expression is expected to be stable and long-lasting, provided that the fusion gene has
been integrated into the host genome, which is true as indicated in previous results. Even
though Pcmv drives strong expression of the transgene, stronger and cell specific
promoters can be used to optimize the expression of the fusion protein. A candidate
could be the GFAP (glial fibrillary acidic protein) promoter in the glial cell line PO-D17.
GFAP promoter driven expression of the transgene can offer cell specific expression and
tight regulation within glial cells (Morelli et al. 1999).

B. Renilla Luciferase Reported RUC-GDNF Production in vivo
1. Bioassay failed to detect GDNF in cisternal CSF
No visible neurite outgrowth could be seen in DRG cell culture treated with 10 pi
CSF of 72-hour post-implantation. The explanation may be that the concentration of the
RUC-GDNF fusion protein is too low to exert any effect. According to the regression
equation, the average photon count of approximately 60,000 is equivalent to 0.2pg/15 pi
GDNF in CSF. This concentration of GDNF is above the published minimum
therapeutic concentration of GDNF, which is 10 pg/ml (Bohn 1999). A further dilution
of the small volume of CSF by addition of necessary serum-free medium in order to
culture the DRG cells has however lowered GDNF concentration by at least 50 fold.
Since the volume of day-3 CSF was not sufficient for both GDNF bioassay and RUC
assay, the photon reading was not taken, instead, it was estimated based on the time
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course curve, which might be higher than that of day-2. Another explanation for negative
GDNF bioassay is that CSF may contain inhibitors for GDNF, this finding however is not
supported by any published data.
2. ELISA and Western blotting failed to detect GDNF in CSF
Five day-3 CSF samples with up to 15pl (average 10 pi) volumes were used for
GDNF ELISA and GDNF Western blotting. With experimental conditions much the
same as in experiments using the culture medium, no GDNF could be detected in CSF.
For the same reason as for the negative GDNF bioassay, GDNF concentration in
day-3 CSF is far below the detection limit of Western blotting (at least 1.0 ng). Although
GDNF concentration in CSF based on the regression equation is 110 pg/ml, more than
the detection limit of 32 pg/ml by the GDNF Emax system, the total amount of GDNF in
10 pi CSF is far below than needed to run ELISA. Furthermore, the RUC activity assay
by photon counting was based on 10-minute exposure, instead of 3 minutes, due to the
very low signal. Therefore, RUC activity in CSF at 3-minute exposure which the
regression equation applies, would be several fold lower than with the 10-minute
exposure.
The negative GDNF assays, i.e., DRG neurite outgrowth, ELISA, Western
blotting are all due to low concentration or total amount of GDNF in CSF. This further
demonstrates that RUC as the reporter offers sensitivity far beyond the detection limits of
the commonly used methods, such as ELISA and Western blotting.
3. RUC activity in C S F
Figure 19 shows the luminescence in 10 pi cisternal CSF following the addition
of 100 pi of 1 pM coelenterazine, before implantation (base line) and at 24 hours, 48
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hours, 5 days, 7 days, 10 days, and 15, 20 and 25 days after implantation. Data show that
RUC activity can be detected 24 hours post-implantation and continues to rise during the
48 hours after implantation. RUC activity gradually declines at day 5, and is back to the
base line at day 15.
According to previous studies (Proescholdt et al. 2000), chemical tracers can be
detected in the brain matrix 4 hours after injection into the cistern. Theoretically the
fusion protein secreted from the implanted cells could be detected several hours
following the implantation. However, repeated cisternal CSF extraction cannot be
performed until the animal regenerates CSF sufficient to recover from the loss of CSF
due to the pre-implantation sampling, and to maintain the physiological CSF pressure.
For this reason, the fusion protein could not be detected earlier than 24 hours post
implantation.
RUC activity in CSF may peak on day-3 post-implantation, instead of day-2,
since day-3 CSF had to be used in ELISA and Western blotting studies. The explanation
for the decline of RUC activity in CSF could be that the implanted cells were rejected by
the host immune system, or the expression of fusion transgene “switched off’. Host
immune reactions in the brain are reduced, compared to the rest of the body, partly due to
the blood brain barrier. However, brain immune responses against cellular transplants are
still observed in mice (Terry et al. 1997). This study revealed histological changes post
implantation similar to that of graft rejection. The implanted glial cells induced an upregulation of major histocompatibility complex (MHC) class I and MHC class II
activation of resident microglia and recruitment of macrophages, and resulted in
astrocytosis. The early immune reactions seemed to gradually decrease and implants
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survived the rejection. Many factors are involved in the expression level of a foreign
gene from a recombinant plasmid, e.g., strength of the promoter/enhancer system driving
transcription, mRNA stability, efficiency of 3’ processing, and gene dosage. The
expression level can be significantly improved by utilizing an amplification promoting
element, muNTSl to increase copy numbers by up to 800 fold (Hemann et al. 1994).
Use of adenovirus mediated gene transfer may also improve the expression efficiency
(Barkats

a/. 1998).

4. RUC activity in brain homogenate
At day 15, the homogenate of three randomly selected brains showed an average
RUC activity of 102,409 photon counts/lOmin exposure (97,504 to 145,536) on the
injection side, while on the contralateral side of the brain, the average RUC activity was
45,998 (38,564 to 50,102). The cerebellum as the negative control showed an average
RUC activity of only 11,788 (9,023 to 11,949).
The residual RUC activity in brain homogenate suggested that the remaining
production of the RUC-GDNF fusion protein by RG-1 cells was not sufficient to diffuse
into the CSF and reach a concentration above the detection limit of the imaging system.
The other interesting finding is that the RUC activity was detected in the contralateral
brain. This strongly suggests that the implanted cells migrated from the implantation site
to the contralateral side.
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CHAPTER IV. CONCLUSIONS AND FUTURE STUDIES
A. Conclusions
This study achieved three goals:
a. The construct has been made to transfect mammalian cells to express the RUCGDNF fusion protein.
b. The expressed fusion protein retains bioactivities of both RUC and GDNF, upon
secretion from mammalian cells.
c. Cellular implantation produced detectable RUC activity in CSF.
It is expected that the modified RG-1 cell line that is optimized for RUC-GDNF
expression and longevity can be used to monitor the implanted cells in Parkinson’s
disease. We expect that the implanted cells will offer protection to dopaminergic neurons
and reverse the disease progression of PD in patients. Researcher and clinicians can
obtain information of the longevity of the implanted cells by a simple “lumbar tap” to
measure RUC activity in CSF. PD is not the only disease that could be treated with RG-1
cellular implantation. A recent study using dorsal root ganglion cells has demonstrated a
potent analgesic effect of GDNF in neuropathic pain states (Boucher et al. 2000).
Intrathecal implantation of RG-1 could be expected to alleviate the severe and refractory
pain due to peripheral nerve damage.
The fusion protein from RG-1 cells can also be used in GDNF receptor studies.
When the ligand, GDNF that is fused with RUC, binds to the receptor, the concentration
of receptor can be measured simply by adding coelecterazine to the reaction and
quantifying the light emission.
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The self-reporting feature offered by this cell system would also enable the
researcher to study the relationship between implanted cells and the relief of PD
symptoms and disease progress. In the past this was impossible to accomplish because
cells could not be retrieved for study until death of the subject.
The principles revealed in this study also apply to gene therapy with other
recombinant proteins, such as tryrosine hydroxylase (TH) that enhances dopamine
synthesis in the treatment of PD, and brain derived neurotrophic factor (BDNF) that
promotes cholinergic neuron survival in the treatment of Huntington’s disease, and so on.
As in the fusion protein RUC-GDNF, these proteins can be fused with RUC or some
other type of reporter protein to achieve the intrinsic monitoring capability. We expect
that the protein fusion technique will be widely used to engineer proteins with functions
other than those observed in native proteins. Adding a reporter to an existing protein has
been shown to be effective and reliable in this study, and may give rise to various
applications in brain research in the future.

B. Future Studies
Future studies utilizing the RG-1 cell line in PD gene therapy should be directed
toward 1) optimization of cell survival and/or sustained gene expression; 2) examination
of brain response to implantation and GDNF production; 3) implantation into an animal
models of PD; and 4) cell migration studies in live animals.
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APPENDIX A. PUBLICATIONS

The attached article describes my previous research on Parkinson’s disease. This
study indicated that PD involves multi-neurotransmitters including dopamine, as well as
serotonin. Gene therapy therefore should target on not only dopamine degeneration, but
also other type of neurons, such as serotonergic.
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This study addresses two issues: (1) the comparative neurochemistry of classic tremor type of
Parkinson's disease or PD-A and akinetic type of Parkinson’s disease or PD-B; and (2) the
neurochemistry of ievodopa failure syndrome (LDFS). Cerebrospinal fluid from the lateral ventricle
was collected from 50 patients with idiopathic Parkinson’s disease of PD-A and PD-B. Levels of
monoamine neurotransmitters and metabolites were determined using high performance liquid
chromatography. We have found that (1) 5-hydroxyiindoieacetic acid (5-HIAA) level is significantly
lower In PD-B than in PD-A; (2) 5-HIAA level Is inversely associated with score of part one of United
Parkinson’s Disease Rating Score (UPDRS); (3) 5-HIAA level is inversely associated with score of part
four of UPDRS; (4) 3-Omethyidopa (3-OMD) level is positively associated with Ievodopa failure
syndrome (LDFS) assessed by part four of UPDRS and inversely associates with S-HIAA. From these
data, it can be inferred that serotonergic activity is decreased in PD-B to a greater extent than in PD-A
and that decreased serotonergic activity plays a role in LDFS. «• isss Atomic w***

failure syndrome (LDFS). This syndrome is character
ized by a cluster of symptoms that occur after intensive
supplemental administration of Ievodopa. It is mani
fested by symptoms either incited by. or unresponsive
to Ievodopa. These symptoms include dyskinesia,
motor fluctuations, resistant akinesia, and possible
accelerated progression of the disease itself (Cedarbaum and Schleifer, 1990) and various symptoms not
classically linked to LDFS but occur with disease
progression, such as sleep disturbance, increased fa
tigue, neuroasthensia, and high prevalence of depres
sion and neurocognative defects, which may reflect the
involvement of neurotransmitters besides DA, e,g„
5-HT and norepinephrine. Clinical observations reveal
that therapeutic efficacy is lost in greater than 50% of
the patients 3 to 5 years after initial treatment with
Ievodopa, and 80% experience some of the motor and
cognitive side effects associated with Ievodopa therapy
within a year of the initiation of treatment (Poowe,
1993).

INTRODUCTION
Idiopathic Parkinson's disease (PD) is a progressive
neurological disease with many associated movement
symptoms. The primary neurochemical basis of the
disease is linked to progressive loss of central dopa
mine containing neurons. This "dopamine deficiency"
hypothesis is supported by two lines of evidence; (1)
Reserpine, which depletes both serotonin (5-HT) and
dopamine (DA), has been reported to cause a parkin
sonism-like syndrome as a dose dependent side effect
(Hornykiewicz, 1973, 1993); prior to the onset of
symptoms there is an 80-95% loss of dopamine in the
striatum in PD patients (Hsu and Fahten, 1976; Narabayashi, 1995); (2) the discovery of the therapeutic
efficacy- of Ievodopa in the alleviation of the symptoms
associated with Parkinson's disease.
Although the dopamine deficiency hypothesis is
supported by both clinical and pathological findings,
this hypothesis alone cannot explain the Ievodopa
€969.99$ L9J $30.06
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The decreased effectiveness of levodopa on previ
ously responsive symptoms and the emergence of new
symptoms suggest that a loss of other neurochemical
mediators may also be involved in PD development
and its progression. One possibility is a serotonergic
decompensation which may occur as a result of long
term levodopa therapy, leading to a progressive degen
eration of serotonergic nuclei, especially those project
ing from the dorsal raphe nucleus to the striatum. Data
from numerous groups have supported the idea that
5-HT may play an important role in PD (Davidson et
al, 1977; Dray, 1981; Durif et al, 1995; Gumpert et al,
1973; Halliday et al, 1990; lacono et al, 1997b; Langdon
et al, 1986; Melamed et al., 1996; Papeschi et al, 1972;
Tohgi et al, 1993,1997), Supporting the above studies,
over 90% of the dorsal raphe nuclei that project to the
basal ganglia have degenerated in patients who have
died of complications due to PD (Starkstein d al,
1998).
Recently, it has been proposed that PD symptoms
may be grouped into at least two types based on clinicaf manifestations and neurochemistry evidence (la
cono d al, 1995b, 1997b). The classic tremor-dominant
type of Parkinson's disease, or PD-A, presents with a
dominance of hyperkinetic motor symptoms such as
tremor, dyskinesia, cogwheel rigidity, and these symp
toms respond to levodopa therapy. The akinetic type of
Parkinson's disease or PD-B is characterized by absente of tremor with predominantly akinetic motor
symptoms such as bradykinesia, akinesia, and pos
tural instability, which do not respond well to levo
dopa therapy, compared to PD-A (Jankovic et al., 1990;
lacono et al, 1997b). Our observations (unpublished
data) show that patients of PD-B, besides dominant
akinetic motor symptoms, typically report antecedent
major life stress events and often major elements of
depression by history, of which serotonin deficiency
plays a significant role (Melamed et al, 1996).
In this present study we measured levels of both
dopamine- and serotonin-related metabolites in human ventricular CSF in order to test two hypotheses:
(1) serotonergic deficiency is associated with the aki
netic and axial symptoms commonly seen in the PD-B;
(2) serotonergic deficiency is associated with LDFS in
advanced PD-A and this deficiency is associated with
levodopa therapy, indicated by 3-O-methyldopa (3OMD) level in CSF.

an anonymous retrospective basts after a general

written consent was obtained in accordance with the
requirement of Institutional Review Board of Lome
Linda University, Diagnosis was made based on the
diagnostic criteria adopted from jankovic et at. (1990)
and lacono et nl. (1995b, 1997b) as shown in Table 1.
None of the patients had overt dementia or depression.
All patients were fasted overnight prior to surgery and
had been administered their last dose of levodopa/
carbidopa 12 to 16 h prior to CSF withdrawal.
Collection of ventricular CSF (vCSF) was as previ
ously described (lacono et at, 1995a, 1995b, 1997a,
1997b). Briefly, vCSF samples were obtained through a
catheter positioned in the foramen of Monroe. The
samples were collected prior to an equal volume of
positive contrast injection for ventriculogram. A total
of 3 ml of blood-free CSF was collected from each
patient and immediately frozen in liquid nitrogen and
later transferred to — 80°C for up to 1 month until
analyzed.
Serotonin, 5-hydroxylindolacetic acid (5-HIAA),
5-hvdroxytryptophan (5-HTP), homovanilic acid
(HVA), and 3-OMD were measured by reversed phase
high pressure liquid chromatography (HPLC) with
electrochemical detection using a modified method
adopted from Wester d al. (1990). Standards were
purchased from Sigma and were made in 0.1 N
perchloric arid. Samples were deproteinized by add
ing 0.1 N perchloric acid 7 //! per 100-/d sample and
centrifuged in mkrofilterfuge tube with the pore size
of 0.2 /nn. One hundred microliters of deproteinized
vCSF sample was directly injected onto an ESA EC-II
HPLC system. Data was collected and recorded by
Rainin Dynamax Madntegrator.
All statistical analyses were performed using Statis
tical Program for Social Science (SPSS) Version 8,0 for
Windows. The distribution of each variable for each
type of patient was checked before comparison and
correlation analyses. Independent t test was per
formed to compare group means if the variable was
TABLE 1
Diagnostic Criteria
PD-A
PD-B

METHODS
Fifty patients diagnosed PD-A or PD-B and with
indications for pallidotomy were randomly selected on
Copyright« 1999 by Academic Press
Ail rights at reproavetiors in any form reserved.
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Onset with tremor, cogwheel rigidity progression with bra
dykinesia, akinetic and axial symptoms, "on-off" and
LDFS. Good response to levodopa
Onset without t remor, predominance of axial, akinetic and
postural Instability. Antecedent major life stress events
and often major elements of depression by history. Fair
to good response to levodopa. Good response to selec
tive serotonin reuptake inhibitors (SSRls) for associated
symptoms
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normally distributed and had equal variance as indi
cated by Levene's test. Nonnormal distributed data
{5-HIAA) were log transformed before t statistic. Corre
lations were independently assessed within PD-A and
PD-B populations, and Pearson correlation was per
formed if two variables did not violate the normal
distribution and equal variance assumptions, or the
Spearman rank order correlation was used if one or
both variables were not normally distributed. In all
cases statistical significance was assumed at P < 0.05.

TABLE 3
Ventricular CSF Concentrations in pg/100 //I of the Serotonin
and Dopamine Metabolites
PD-A (mean ± SD) (n = 30) PD-B (mean ± SO) (>» * 20)
77 t 108
6226 =: 2493a
82 ± 43
21474 i 18184
46130 x 22206

69 z 46
11509 ± 6544
84 z 37
21629 x 15374
39530 z 16780

5-HT
5-HIAA
3-HTP
HVA
3-OMD

“Significant difference between IT3-A and PD-B groups, indepen
dent / lest on log-transformed data; P < 0.05.

RESULTS

3-OMD are shown in Figs. 2A-2D. As shown in Fig.
2A, there was a negative relationship between vCSF
5-HIAA level and UPDRS-I in PD-A (Spearman's
rho ~ -0.45, P < 0.05) but not significant in PD-B. The
5-HIAA level was also negatively related to UPDRS-IV
in PD-A (Spearman's rho — -0.55, P < 0.01) (Fig. 2B).
In Fig. 2C, 3-OMD level is positively associated with
UPDRS-IV in PD-A group (Pearson r - 0.47, P < 0.05),
but not statistically significant in PD-B. Figure 2D
illustrates that 3-OMD level is negatively associated
with 5-HIAA in PD-A (Pearson r = -0.42, P < 0.05),
but only shows a negative trend in PD-B.

All subjects were under levodopa treatment. The
distribution of age, gender, duration of disease, levo
dopa dosage, and disease severity measured by UPDRS are presented as mean ± SD as shown in Table 2.
No significant differences were detected in these vari
ables between PD-A and PD-B by t test.
As summarized in Table 3, there were no significant
differences between PD-A and PD-B patient popula
tions with respect to 5-HT 5-HTP, HVA, and 3-OMD.
The vCSF concentration of 5-HIAA was significantly
lower in PD-B patient group compared with the PD-A
patient group (P < 0.05) (Table 3 and Fig. 1).
Results of correlation analyses for 5-HIAA and
UPDRS-I or IV, 3-OMD and UPDRS-IV, 5-HIAA and

DISCUSSION
The most significant findings in this study reveal
that (1) compared to PD-A, PD-B tends to have a

TABLE 2
Subject Information
PD-A (mean z SD) PD-B (mean t SD)
N
Male
Female
Age (year)
Duration (year)
Levodopa Dose (mg/day)
UPDRS-I* (onf
UPDRS-I P (on)
UPDRS-llP (on)
UPDRS-IV' (on)
UPDRS-TotaP (on)
Progression Score*

30
24
6
64.9 ± 7.9
9.8 ± 4,9
894 z $33
4,6 ± 3.0
14.7 ± 7.8
17.9 Z 7.5
7.3 ± 3.4
44.2 Z 17.3
5.3 ± 2.8

20
13
7
62.) z 12,1
9.5 ±4.2
808 ± 450
.4.3 X 2 A
14.8 ± 8.7
19.8 ± 10.7
8.4 z 5.4
47.1 X 18.8
6.2 2- 3.4

14000-

3 12000 -

8

*3
^

1000080006000 -

tA
tw

5

<tLiPDRS-t, measures thought memory, depression, and motivation.
A)n, period when medication is effective.
‘UPDRS-II, measures motor symptoms (tremor, gait, etc.) in
history.
■'UPDRS-UI, measures motor symptoms (tremor, gait, etc.) during
physical examination.
•UPDRS-IV, measures dyskinesia and "on-off" (LDFS).
’UPDRS-total - sum of UPDRS-1 through UPDRS-IV.
Progression score - UPDRS-total/duration of disease (years).

40002000-

oi

i

PD-8

PD-A
PD Type

FIG. 1. Levels of 5-H1AA in vCSF are significantly higher In PD-A
(n = 30) tlian PD-B (» «19), P < 0.05. Bars represent mean 5-HIAA
levels, error bars represent standard errors of means in PD-A and PD-B.
Copyright ® (999 try Academic Press
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significant in PD-B (r-0,41, p>0,05)
statistically significant in PD-8 (Spearman’s rho *
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FIG. 2. Scatterplot and correlations between 5-HIAA, 3-OMD and UPDRS-I and IV. A high score in UPDRS-I indicates severe disturbances in
mood and cognitive functions, A high score in UPDRS-tV indicates severe levodopa failure syndrome (motor fluctuations, dyskinesia, etc.) •,
PD-A; A, PD-B; solid line, PD-A; dotted line, PD-B.

severely decreased 5-HT activity indicated by dimin
ished vCSF 5-HIAA; and (2) in PD-A, greater LDFS
severity' indicated by part four of UPDRS is associated
with lower 5-HIAA and higher 3-OMD in vCSF.
Our data suggest that PD-B has a lower serotonergic
activity than PD-A, This may explain the emotional
and cognitive deficits that are commonly seen in PD-B.
A recent clinical study reveals that patients with
predominant akinetic features report significantly
higher rate of major depression than patients with
Copyright *> 19S9 by Acsdemic Press
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classic tremor-type PD (Melamed el ai., 1996). It has
been proposed by the same authors that other symp
toms that often accompany PD-B such as depression,
loss of appetite and weight, sleep disturbances, persis
tent occurrence of nausea and vomiting, somnolence,
yawning, vivid dreams, myoclonus, and hallucinosis
are ail related to serotonergic dysfunctioning (Mela
med el al, 1996). Treatment of such symptoms is the
addition of one of the selective serotonin reuptake
inhibitors (SRI), Interestingly, SSRI has been reported
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to be effecti ve in treating cataplexy as well (Langdon et
at, 1986), and our observation has shown the hypoki
netic symptoms of akinesia and bradykinesia, mani
fested as gait disorders, including gait freezing, pos
tural instability, and masked faces experience significant
alleviation following the administration SSRIs (lacono
el at, 1994). This evidence, along with the observations,
suggest that there is a serotonergic mechanism in PD of
cognitive, emotional, as well as motor disturbances.
However, we do not have an explanation why in PD-B,
UPDRS-I which estimates cognitive and emotional
deficits is not associated with vCSF 5-HIAA, as in
PD-A (Fig. 2A).
Our data support the idea that 5-HIAA may be a
better indicator for levodopa therapeutic response
than HVA. It was also reported by Davidson et al. that
patients who become functionally independent on
treatment with levodopa had higher 5-HIAA levels in
lumbar CSF than patients who showed no such im
provement, which implies that intact serotonergic
neurons may be important in the therapeutic response
to levodopa (Davidson et al, 1977; Dray, 1981; Gumpert
et al, 1973). The supporting data is shown in Figs. 2A
and 2B, in which PD-A shows a significant inverse
relationship between 5-HIAA and UPDRS. This could
explain why the response to levodopa in PD-B is not as
good as in PD-A. This could also explain why in PD- A,
the response to levodopa gradually decreases, know
ing that serotonergic loss gradually becomes apparent
as the disease progresses.
Loss of serotonergic activity is supported by postmor
tem pathological studies which have shown a signifi
cant loss of serotonergic neurons in discrete nuclei in
the dorsal raphe nuclei and median raphe nuclei in PD
patients (Yeh and Brown, 1977), and this loss can be as
high as over 90% (Halliday et al, 1990). Halliday's
study also revealed a variable distribution in the loss of
serotonergic neurons among the subjects. It is possible
that this variety reflects the difference in the degree of
toss of serotonergic neurons in PD-A and PD-B, since
this study did not distinguish subtypes of PD.
Earlier studies have also shown the administration
of 5-HTP to PD patients tends to reduces dopamine
levels (McGreer et al, 1963). Tohgi et al found that
there was significant reduction in the total 5-HT in
lumbar CSF and total 5-HT had significant negative
correlations with Hoehn/Yarh's (H/Y) stages and
grades of rigidity, akinesia, and gait freezing (resem
bling PD-B), but not of tremor (resembling PD-A)
(Tohgi et al, 1993). Papeschi et al, (1972) reported HVA,
5-HT, and 5-HIAA levels in ventricular CSF in PD

patients showed negative correlations between these
metabolites and the disease severity. In our previous
study we found significantly higher concentrations of
5'HTP and lower concentrations of 5-HT in vCSF in
PD-B than PD-A patients, indicating that in PD-B,
there may be a defect in the activity of 5-HTP decarbox
ylase (lacono et til, 1997b). In their recent report/ Tohgi
et ol. revealed that in the so-called "vascular parkinson
ism," which closely resembles the symptomatology of
PD-B, 5-HT levels in CSF are significantly lower than
that in PD resembling PD-A (Tohgi et at, 1997). The
explanation that we failed to detect 5-HT difference
between PD-A and PD-B might be that in this study
free 5-HT was measured, instead of total 5-HT, which
was measured in Tohgi's study (Tohgi et at, 1993).
Total 5-HT is reported to be eight times higher than
free 5-HT (Tohgi et at, 1993), which therefore could
enable us to detect the difference. In this present study,
the correlation of 5-HT and progression was not
statistically significant within either PD-A or PD-B.
This might be because of the great within-group
variations and relative small size of cases. We could
expect decreased 5-HT to associate with progression in
both groups with larger samples.
This study also addresses the role of serotonin in
LDFS. The relationship between 5-HT and LDFS has
been ignored. It has been shown, however, that admin
istration of levodopa causes a reciprocal reduction in
5-HT (Wesemann et at, 1993), whereas significant
improvement was reported of apomorphine-indueed
dyskinesias after fluoxetine treatment (Durif et «/.,
1995). These studies gave insight to the possible seroto
nin involvement in LDFS and inhibition of serotoner
gic activity by levodopa therapy. This reasoning is
supported by data presented here. Since our data also
demonstrates that 3-OMD in vCSF is associated with
both LDFS and 5-HIAA levels, it appears reasonable to
postulate that the accumulated 3-OMD in the brain
may also adversely affect serotonergic activity by an
unknown mechanism contributing to the LDFS.
Studies on 3-OMD are abundant, yet results have
been contradictory. Being one of the major metabolites
of levodopa in both peripheral tissues and the brain,
3-OMD has been studied extensively as a result of
levodopa therapy. In lumbar CSF, concentrations of
3-OMD was found significantly increased after levo
dopa administration (Tohgi et at, 1991, 1993). White
some studies report high plasma levels of 3-OMD in
parkinsonian patients chronically treated with levo
dopa, particularly in those with on-off phenomenon,
others did not reveal a relationship between plasma
Copyright i-1939 by Academic Press
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levels of 3-OMD and on-off phenomena (Bowes et al,
1991; Fabbrini et a!., 1987; Luquin et al, 1989; Lewitt et
a!., 1992). It appears rational to reason that 3-OMD may
compete for blood-brain barrier with Ievodopa so that
Ievodopa into the brain is decreased (Benetello et al,
1997; Himori and Mishima, 1994), which could cause
motor fluctuations. However, this suggestion is not
consistent with yet another study, It has been reported
by Tohgi's group that after Ievodopa treatment, the
ratio of dopamine to 3-OMD was significantly shifted
in favor of 3-OMD in patients with the on-off com
pared with patients without the on-off, but concentra
tions of Ievodopa, DA, and HVA were not different
between the groups, suggesting that even if 3-OMD is
related to the pathogenesis of the on-off, it is not
through competition with Ievodopa for uptake into the
brain, but through other unknown mechanisms within
the brain (Tohgi et al, 1991). Recent experimental
application of catechol-O-methyltransferase (COMT)
inhibitors has shed light on the role of 3-OMD. These
drugs are capable of inhibiting the generation of
3-OMD (Dingemanse et al, 1995; Mizuno et al, 1994)
and improve the bioavailability of Ievodopa in human
subjects (Brautigam et al, 1994; Ruottinen and Rhine,
1996a; Yamamoto et al, 1997; Lyytmen et al, 1997),
therefore improve response to Ievodopa therapy (Davis
et al, 1995; Ruottinen and Rinne, 1996b; Gottwaid et al,
1997). However, to this date, we are not aware of any
studies examining the possible correlations between
COMT inhibitors and the metabolisms of other mono
amines such as serotonin.
We propose, based on the data reported here, that (1)
PD-B has a unique neurochemical process in which
decreased serotonergic activity forms one of the pri
mary deficiencies that maybe associated with akinetic
symptoms and progression of disease; and (2) in PD-A,
there exists a serotonergic compensation during the
early stages, but serotonergic deficiency eventually
occurs as a result of progressive pathological loss of
serotonergic cell bodies and as a result of intensive
Ievodopa therapy. This "dual deficiency theory" (DA
and 5-HT) has been shown in PD studies by Barbeau
(1962) and long suspected by us in advanced and
akinetic PD patients. Data reported here dearly demon
strate that CNS serotonergic activity, as indicated by
vCSF 5-HIAA, is different between the two major
types of PD (A and B). The fact that only patients not
receiving SSRI were recruited suggests that the differ
ence can only be (1) real neurochemical difference
between the two types of PD; or (2) consequence of
Ievodopa therapy. Since the dosage of Ievodopa for
both types of patients is of no statistical difference, the
Copyright« 1999 by Academic Press
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second possibility is unlikely to be the cause. It is
possible that in PD-A, the serotonergic compensation
mechanism is triggered by the significant loss of
dopaminergic activity, demonstrated in Table 3 and
Fig. 2A. This is consistent with the animal study using
chronic low-dose MFTP in monkeys (Schneider, 1990),
in which serotonin levels in striatal regions were found
to be significantly increased after monkeys were ex
posed to chronic low dose of MPTP. In contrast to
PD-A, PD-B may have a primary loss of serotonergic
activity or dual monoaminergic deficiency of serotonin
and dopamine. If that is the case, it should be expected
that vCSF 5-HIAA levels in PD-B be lower than in
PD-A. As for the relationship between 3-OMD and
serotonergic activity, which represents the effect on
serotonin from ievodopa therapy, it is possible that
since structurally 3-OMD closely resembles a-methyldopa and carbidopa, which are known to inhibit
decarboxylase, 3-OMD might possess similar inhibi
tory effect on decarboxylase (Porter et al, 1962). If this
is true, then 3-OMD might also suppress the produc
tion of 5-HT, as well as 5-HIAA, which are known to be
associated with LDFS. Furthermore, if 3-OMD does
inhibit 5-HT production, it may be hypothesized that
its inhibitory effect be more pronounced clinically on a
compensating serotonergic activity, presumably in
PD-A. This hypothesis is supported by the data shown
in Figs. 2A-D.
To summarize, these results (1) add further support
for the hypothesis that serotonergic deficiency forms
the basis for the distinctive subtype of tire akinetic PD
or PD-B (lacono et al, 1997b); (2) evidence for the
hypothesis that decreased serotonergic activity is part
of the mechanism for LDFS; (3) suggest that the
accumulation of 3-OMD in the brain may cause or
enhance the decreased serotonergic activity.
Up until now, one of the problems with 5-HT studies
in PD is that no distinction has been made to differenti
ate PD-A and PD-B. The value of this paper is to
differentiate a subtype with possible extensive seroto
nin loss, possibly early in disease duration. In the
future, disease progression and subtype must be distin
guished in studies of 5-FIT in PD.
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